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Identification And Functional Characterization Of Novel Determinants
Of The Somatotropes And Lactotrope Lineages In The Anterior Pituitary
Abstract

The differentiation of the hormone-producing cell lineages of the anterior pituitary represents an informative
model of mammalian cell fate determination. The generation and maintenance of two of these lineages, the
growth hormone (GH) producing somatotropes and the prolactin (PRL) producing lactotropes, are
dependent on the pituitary-specific transcription factor, POU1F1. While POU1F1 is expressed in both cell
types, and plays a direct role in the activation of both the Gh and Prl genes, GH expression is restricted to
somatotropes and PRL expression is restricted to lactotropes. These observations imply the existence of
additional, cell type-enriched factors, that contribute to the somatotrope and lactotrope cell identities. Here,
we use transgenic mouse models to facilitate sorting of somatotrope and lactotrope populations based on the
expression of fluorescent markers expressed under Gh and Prl gene transcriptional controls. The
transcriptomic analyses reveal a concordance of gene expression profiles in the two populations. The limited
number of mRNAs that are selectively enriched in each of the two populations includes a set of transcription
factors. A subset of these factors may have roles in pituitary lineage divergence, and/or in regulating
expression of cell-type specific genes after differentiation. Four of these factors were validated for lineage
enrichment at the level of protein expression, two somatotrope-enriched and two lactotrope-enriched. Three
of these four factors were shown to have corresponding activities in appropriate enhancement or repression of
landmark somatotrope or lactotrope genes in a pituitary-derived cell culture model system. Conditional
inactivation of the genes encoding these factors in mice revealed that two of these transcription factors impact
the expression of landmark hormone genes and alter cell phenotypes in primary murine pituitary. Subsequent
mechanistic studies revealed that these two factors act on their target genes either through a direct binding at
the target promoter and release of paused Pol II complexes, or through indirect mechanism(s). The functions
of these two factors are further remarkable in how they maintain hormone expression in the lactotrope and
somatotrope lineages; one serves to enhance landmark Prl gene expression in lactotropes while the second
serves to reciprocally repress expression of the Prl gene in somatotropes. In conclusion, these studies identify
novel regulators of the somatotropes and lactotropes, explore their mechanisms of action, and establish a
useful database for further study of these lineages in the anterior pituitary.
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ABSTRACT
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF
NOVEL DETERMINANTS OF THE SOMATOTROPE AND
LACTOROPE LINEAGES IN THE ANTERIOR PITUITARY
Michael T. Peel
Stephen A. Liebhaber

The differentiation of the hormone-producing cell lineages of the anterior
pituitary represents an informative model of mammalian cell fate determination.
The generation and maintenance of two of these lineages, the growth hormone
(GH) producing somatotropes and the prolactin (PRL) producing lactotropes, are
dependent on the pituitary-specific transcription factor, POU1F1. While POU1F1
is expressed in both cell types, and plays a direct role in the activation of both the
Gh and Prl genes, GH expression is restricted to somatotropes and PRL
expression is restricted to lactotropes. These observations imply the existence of
additional, cell type-enriched factors, that contribute to the somatotrope and
lactotrope cell identities. Here, we use transgenic mouse models to facilitate
sorting of somatotrope and lactotrope populations based on the expression of
fluorescent markers expressed under Gh and Prl gene transcriptional controls.
The transcriptomic analyses reveal a concordance of gene expression profiles in
the two populations. The limited number of mRNAs that are selectively enriched
in each of the two populations includes a set of transcription factors. A subset of
vi

these factors may have roles in pituitary lineage divergence, and/or in regulating
expression of cell-type specific genes after differentiation. Four of these factors
were validated for lineage enrichment at the level of protein expression, two
somatotrope-enriched and two lactotrope-enriched. Three of these four factors
were shown to have corresponding activities in appropriate enhancement or
repression of landmark somatotrope or lactotrope genes in a pituitary-derived cell
culture model system. Conditional inactivation of the genes encoding these
factors in mice revealed that two of these transcription factors impact the
expression of landmark hormone genes and alter cell phenotypes in primary
murine pituitary. Subsequent mechanistic studies revealed that these two factors
act on their target genes either through a direct binding at the target promoter
and release of paused Pol II complexes, or through indirect mechanism(s). The
functions of these two factors are further remarkable in how they maintain
hormone expression in the lactotrope and somatotrope lineages; one serves to
enhance landmark Prl gene expression in lactotropes while the second serves to
reciprocally repress expression of the Prl gene in somatotropes. In conclusion,
these studies identify novel regulators of the somatotropes and lactotropes,
explore their mechanisms of action, and establish a useful database for further
study of these lineages in the anterior pituitary.
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CHAPTER I: INTRODUCTION

1

The abilities to preserve homeostasis and to react to physiological stimuli
are among the most fundamental processes to life. In animals, entire organ
systems are dedicated to regulating and maintaining these processes throughout
the body, and many of these systems interact with each other dynamically. The
endocrine system is a key component of this intricate network of regulation,
signaling to a wide array of organs within the body through signaling molecules
known as hormones. A central regulator of the endocrine system is the pituitary
gland1. The pituitary gland is a small endocrine gland located at the base of the
brain sometimes referred to as the “master gland” due to its central role in
regulating a broad range of downstream endocrine functions. The pituitary is
divided into two lobes: a posterior lobe and an intermediate/anterior lobe. Each of
these lobes responds to physiological signals received from the hypothalamus,
and secretes the appropriate hormone into the bloodstream in response to these
signals1,2. Despite its small size, the pituitary produces a broad and diverse set of
hormones, which regulate processes as varied as somatic growth, carbohydrate
metabolism, reproduction, lactation, stress response, and skin pigmentation.
Conventional understanding of the pituitary states that each of the pituitary
hormones is produced and secreted by a dedicated cell type within the gland1,2.
Thus, pituitary cells are not a singular cell type, but rather a set of multiple cell
types occupying the same gland, each receiving specific signals from the
hypothalamus and secreting their respective hormones in response. Within the
anterior lobe of the pituitary, which produces the highest number of hormones of
2

the lobes, all of the cell types arise from a common developmental origin 1,2 (Fig.
1).
The development of the pituitary is most clearly defined in the mouse. At
e9.5, the oral ectoderm begins to invaginate in response to BMP4 expressed by
the nearby diencephalon, forming an invagination known as Rathke’s pouch2.
Within Rathke’s pouch, Gli family transcription factors, namely Gli1 and Gli2, are
crucial regulators of early pituitary development, and deletion of Gli1 and Gli2
causes a complete failure of the pituitary to develop in mice3. The Gli family of
transcription factors is a component of the hedgehog (HH) signaling pathway.
Pituitary development requires Sonic Hedgehog (Shh) expression, as inhibition of
Shh prevents Rathke’s pouch from growing and prevents the development of all
lineages of the endocrine cells of the anterior pituitary4. At approximately e11, the
cells of Rathke’s pouch begin to express a cascade of transcription factors such
as Lhx3, Pitx1, and Pitx21,2,5 , that guide development of endocrine cells within
the developing pituitary. Many stages of anterior pituitary development remain
incompletely understood, and there is conflicting information about the origin of
some cell lineages. However, it is commonly agreed that after e12.5, sets of
transcription factors drive development of the various endocrine cell lineages of
the anterior pituitary from the common precursor cells of Rathke’s pouch1,2.
The most abundant cells in the anterior pituitary are those that belong to
the so-called “Pou1f1 lineages.6” The Pou1f1 lineages comprise three cell types
within the anterior pituitary that all require the expression of the pituitary-specific
3

POU domain transcription factor, Pou1f1, for their development and for their
continued function in the adult pituitary. These cell types, the thyrotropes,
lactotropes, and somatotropes, produce thyroid stimulating hormone, prolactin,
and growth hormone, respectively7-9. Both mice and humans with mutations in
the Pou1f1 gene are characterized by a deficiency of growth hormone, prolactin,
and thyroid stimulating hormone, highlighting that the differentiation and
expansion of all three of these cell lineages share a common reliance on the
actions of Pou1f110,11.
Somatotropes and lactotropes are linked by a particularly close
developmental relationship that remains incompletely understood 1. Pou1f1
expression is first detected in the mouse at e13.5, following activation via an
unknown mechanism by the transcription factor Prop1 which is initially expressed
at e10 2. The subsequent activation of growth hormone (GH) expression can be
detected in the developing pituitary starting at e15.5 2. Prolactin (PRL) becomes
detectable at e16.5, and many PRL positive cells also express GH at this stage
in development, though the amount of these so called “somatolactotropes” varies
across different species1,12,13. These somatolactotrope cells are postulated to
resolve into somatotropes and lactotropes shortly after their appearance at
e16.5, with somatolactotropes constituting only ~1% of all cells in the adult
anterior pituitary14.
Lineage tracing studies have examined the developmental relationship
between somatolactotropes, somatotropes, and lactotropes. The findings of
4

these lineage tracing studies, carried out by a variety of approaches, are
complex. Expression of various reporters under the control of Gh regulatory
elements in mice indicates that a subset of lactotropes originate from cells that at
one point in their development expressed Gh, though estimates of the
percentage of lactotropes with Gh+ origins varies widely from 10% to nearly all
lactotropes15-17. These data suggest that two sub-populations of lactotrope cells
may exist: a population that derives from a Gh expressing progenitor, and a
second population that originates independently of Gh expressing cells.
Reciprocal lineage tracing studies using reporters under the regulation of Prl
elements have found that somatotrope cells do not have a Prl+ developmental
origin. These data thus suggest that lactotropes may be able to arise from
somatotropes, but not vice versa18,19. Studies in which the lineage tracing was
performed by targeted ablation of lactotrope cells in adult mice frequently note an
increase in GH+/PRL+ somatolactotropes during the recovery period, raising the
possibility of somatolactotrope cells being a transitional state in a one-way transdifferentiation between somatotropes and lactotropes rather than a precursor to
both somatotropes and lactotropes19,20. In conclusion, while the exact role of the
somatolactotrope cells remains unclear, it is clear that the somatotrope and
lactotrope cells have a complex and close relationship.
As previously noted, the somatotrope and lactotrope cells both require
expression of the pituitary-specific transcription factor, Pou1f1, for their
differentiation and expansion8. However, the role of Pou1f1 in these cells extends
5

beyond the development of the two lineages. POU1F1 binds directly to the Gh
and Prl promoters in terminally differentiated somatotropes and lactotropes and
is the only clearly defined activator of both genes21. The paradox between the
observation that POU1F1 activates both the Gh and the Prl genes, and yet the
somatotropes and lactotropes exclusively express GH and PRL, respectively,
forms the central issue that this thesis project seeks to address. The fundamental
hypothesis of this study is that additional transcription factors are present in the
somatotrope and lactotrope lineages that in some manner work in conjunction
with POU1F1 activities so that GH and PRL are specifically expressed in their
respective cell lineages.
Despite an understanding of how the somatotrope and lactotrope cells
function at the level of hormone secretion (i.e., knowledge of which physiological
cues and signals from the hypothalamus act on these cells), there are only a few
additional (non-hormonal) genes that are known to be expressed specifically in
the somatotropes or the lactotropes. Several of these genes express key cell
surface receptors that control the expression and/or secretion of each
hormone22,23. Additionally, previous studies have suggested that factors such as
the ubiquitously-expressed repressor NCoR, and the transcription (co)factor
LSD1 have opposing functions in the somatotropes and lactotrope cells24,25.
Unfortunately, such identification of potential regulators of each lineage originate
primarily from a single laboratory, have not been followed up or confirmed since

6

publication, fail to investigate functional impacts of their identified factors, are
based primarily on cell line models, and lack validation in animal models24,26,27.
In the following studies, we use a variety of orthogonal methods to gain
insight into the crucial differences between the somatotropes and lactotropes at
the level of gene expression. These studies focus primarily on the identification of
novel regulators of both the somatotrope and lactotrope lineages. The results of
these studies are likely to further our understanding of how these two cell types
are able to maintain separate cell identities and selectively express their
corresponding hormone products.

7

Figures and legends

Figure 1. Current standard model of anterior pituitary differentiation in
mouse. The cells of the anterior pituitary begin to differentiate from oral ectoderm
at e8.5. Expression of the transcription factor Prop1 is a precursor to Pou1f1
expression, and Pou1f1 is expressed in all cells encompassed by the bracket.
The somatolactotrope precursor cell arises at e16.5 and differentiates into both
somatotropes and lactotropes (highlighted in blue). The existence of the
hormone-negative Pou1f1+ cell and the triple positive cell type is hypothetical
(dashed lines) and is based on a Tag-capture study from our lab28. This figure is
adapted from2.

8

CHAPTER II: IDENTIFICATION AND VALIDATION OF
NOVEL SOMATOTROPE AND LACTOTROPE ENRICHED
TRANSCRIPTION FACTORS

9

Introduction
The differentiation of multiple cell types from a common precursor cell and
the subsequent maintenance of distinct cell identities throughout adult life are
processes central to most developmental systems29,30. A key question in such
processes is how a common precursor cell can give rise to multiple cell types
with discrete transcriptomic profiles. Cell types differentiating from a common
precursor cell must not only activate transcription of genes necessary for the
appropriate cell fate, but also repress/silence expression of genes that drive
alternate cell identities. The coordination of these opposing regulatory processes
is likely to reflect cell type specific mechanisms of transcriptional control. In
addition, terminally differentiated cells must be subsequently maintained in the
differentiated state throughout adult life. This necessitates sustained
mechanisms and pathways for maintaining cell fate. The establishment and
maintenance of cell fate may be regulated by transcription factors that are
expressed during development and/or by factors that are induced and sustained
during the lifespan of the organism31,32.
The anterior pituitary is an ideal system for studying mechanisms of
lineage establishment and maintenance due to the terminal differentiation and
divergence of somatotropes and lactotropes. In mice, the pituitary-specific master
regulatory transcription factor, POU1F1, is expressed in a subset of developing
pituitary cells beginning at e13.52,33,34. According to a frequently cited model,
these POU1F1+ cells differentiate into the thyroid stimulating hormone (TSH)
10

producing thyrotropes and the GH/PRL dual expressing somatolactotropes at
e16.52,35 (Fig. 1). The somatolactotrope precursor then gives rise to the
terminally differentiated somatotropes and lactotropes, which produce high levels
of GH and PRL protein, respectively36. While small populations of
somatolactotropes remain present in the pituitaries of adult mice, comprising
approximately 1-2% of all cells in the anterior pituitary, their function remains
poorly understood (See Chapter I for more details on somatolactotropes)13,37.
Thus, there is a need to better understand the mechanisms that regulate the
differentiation, expansion, and functions of the somatotrope and lactotrope
populations.
Despite some questions about the pathway of somatotrope and lactotrope
divergence and terminal differentiation, all current models of this pathway agree
that expression of Pou1f1 is essential to the establishment of both populations of
cells and that the somatotrope and lactotrope cells are closely related. In addition
to being a master regulator of the somatotrope and lactotrope lineages, POU1F1
is also a direct activator of both the Gh and Prl genes, and remains expressed in
terminally differentiated somatotropes and lactotropes, driving robust hormone
expression throughout adult life9,21,38,39. Despite this expression of Pou1f1 in both
cell types, the expression of the GH and PRL proteins remains primarily
restricted to the somatotropes and lactotropes, respectively2,40. This observation
suggests the existence of unknown somatotrope and lactotrope specific factors
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that contribute to the divergence and corresponding specificity of gene
expression in the two lineages.
Several genes have been previously identified as lineage-enriched and
essential to the ability of somatotropes and lactotropes to respond to the
appropriate physiological signals to secrete their respective hormones. The
growth hormone releasing hormone receptor, GHRHR, and the dopamine
receptor DRD2 are examples of known receptors expressed on the surfaces of
somatotrope and lactotrope cells, respectively. These cell surface receptors
regulate the expression and secretion of GH and PRL in response to
physiological cues that trigger signaling from the hypothalamus23,41,42. However,
the currently known sets of somatotrope and lactotrope specific genes are
insufficient to adequately explain the mechanism(s) by which the somatotrope
and lactotrope cell identities are established and maintained. Importantly, and
central to this thesis, is the fact that POU1F1 remains the only known
transcription factor that has been reproducibly demonstrated to directly activate
the Gh and Prl genes26,43; some potential activators and repressors have been
suggested but not validated or definitively explored (See Chapter I)24. Taken
together, these observations suggest that there exists a set of currently
unidentified transcription factors that contribute to the respective somatotrope
and/or lactotrope expression profiles. The identification of these factors is
essential to a detailed understanding of the function and pathology of these two
predominant cell types within the anterior pituitary.
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Here we have utilized a set of transgenic mouse lines to facilitate the
isolation of primary somatotrope and lactotrope populations from the adult mouse
pituitary. Transcriptomic profiling of these two cell populations reveals a
noteworthy concordance in their respective transcriptomes. Despite this
transcriptomic similarity, we were able to identify from this analysis approximately
300 genes that are significantly enriched (Log2 fold change >2 and p-value
<0.05) in each of the two cell populations. These enriched genes included a
subset of transcription factors. Six of these transcription factors were selected for
in-depth analysis based on their putative functions. Four of these factors were
confirmed for selective enrichment in primary somatotrope and lactotrope cells at
the level of protein expression. Our data establish a transcriptomic resource for
analysis of somatotrope and lactotrope gene expression and cellular function,
and identify a set of novel cell-type enriched transcription factors that have
potential roles in regulating the expression of landmark hormone genes.
Results
Establishing the transcriptomes of flow sorted somatotropes and
lactotropes.
The goal of this work was to identify novel transcription factors involved in
the maintenance of cell identity in the terminally differentiated somatotropes and
lactotropes. This goal was approached by marking primary cell populations in the
adult mouse pituitary with transgene-encoded fluorescent proteins. Somatotrope
cells were tagged with a GFP reporter under the control of the human growth
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hormone promoter and its upstream locus control region (LCR)44, while
lactotrope cells were tagged by a DsRed reporter regulated by the rat Prl
promoter and upstream sequences (Fig. 2A). These regulatory elements have
been previously demonstrated as sufficient to define somatotrope and lactotropespecific expression in mice45,46. Modifications were made to the GH-GFP cosmid
using conventional sub-cloning techniques to truncate the growth hormone signal
peptide (see Methods), allowing accumulation of GFP in somatotrope cells
rather than secretion, thus improving the GFP signal in this mouse line
(Supplemental Figure 1). The somatotrope specificity of this modified Gh-GFP
line was validated by immunofluorescence microscopy (Supplemental Figure
2). 6-8 week old virgin female compound transgenic mice carrying the Gh-GFP
and Prl-DsRed transgenes were generated for analysis. The use of compound
transgenic mice permits the isolation of somatotropes and lactotropes from the
same mouse pituitaries simultaneously, allowing the direct comparison of
somatotropes and lactotropes with a minimization of experimental variables. The
use of females in these studies ensured our ability to isolate appreciable
numbers of lactotropes for subsequent analysis. These females were analyzed at
6-8 weeks; at this point in “adult” life the pituitary has fully matured and
established the full array of resident cell lineages47,48. 5-6 pituitaries were
collected for each RNA-seq analysis, and these pituitaries were pooled and
FACS sorted into GFP+ and DsRed+ populations (Fig. 2B).
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The study was carried out in biological triplicate, beginning each
independent study with a new set of compound transgenic mice. RNA was
extracted from each of the two flow sorted cell populations and libraries were
generated using low cell input methods (see Methods for more details). The
RNA-seq data from these three biological replicates were then pooled and the
composite transcriptome data set was used to establish the RNA profiles for the
GFP and DsRed cell sorts. The use of a composite transcriptomic data set
allowed for statistical analyses that aided the process of selecting genes of
interest from the data set based on the robustness of their enrichment in each of
the replicate samples. The enrichment of somatotropes or lactotropes in the flow
sorted cell populations was confirmed by comparing the relative levels of anterior
pituitary hormone gene expression in the GFP+ and DsRed+ populations to the
expression of these hormone genes in total pituitaries from virgin female, agematched controls (Fig. 2C). These analyses included all hormone-encoding
genes of the anterior pituitary, including pro-opiomelanocortin (Pomc), the beta
subunits for thyroid stimulating hormone (Tshb), luteinizing hormone (Lhb), and
follicle stimulating hormone (Fshb), as well as the shared heterodimerizing alpha
subunit (Cga). Combined with Gh and Prl, these genes represent the full set of
anterior pituitary hormones and serve as markers for each of the cell lineages of
the anterior pituitary. Gh expression was enriched in the GFP+ samples while the
expression of all other hormone genes was depleted as compared to total
pituitary. Similarly, Prl expression was enriched in DsRed+ samples over the Prl
expression observed in total pituitary. These data demonstrate that the described
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FACS procedure yields cell pools that are highly enriched for the somatotrope
and lactotrope cell populations.
A second set of analyses of the transcriptomic data assessed the relative
expression of sets of well-characterized marker genes that define the
somatotrope and lactotrope lineages. A plot of three known markers for each cell
type as well as five genes expected to be expressed at similar levels in both cell
types (Fig. 3A) revealed that each of the somatotrope and lactotrope marker
genes was appropriately enriched in its respective GFP+ or DsRed+ cell pool
while genes known to be shared in the somatotrope and lactotrope lineages were
expressed at approximately equal levels in both populations. GFP and DsRed
reads were also appropriately enriched in each population, confirming proper
FACS sorting by fluorescent reporter (Supplemental Table 1). Together, these
data indicate that the transcriptomic data set is consistent with the assignment of
somatotrope and lactotrope cell identities to the GFP+ and DsRed+ labeled
populations, respectively2,16,22,49-51.
The concordant transcriptomes of the flow sorted somatotropes and
lactotropes reveal a limited subset of lineage-enriched transcription
factors.
Comparison of the transcriptomes of the flow sorted GFP+ and DsRed+
cell pools reveals a striking level of concordance in gene expression (Fig. 3B).
The overall Pearson correlation value for somatotropes vs. lactotropes was
calculated as 0.42. However, the expression of Gh and Prl in these cells is so
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robust (note their extreme outlier positions on a log2 scale in Fig. 3B) that these
two transcripts markedly skew the Pearson R value and distort the overall
transcriptomic comparison. Removing Gh and Prl from the correlation
calculations yields a Pearson R value of 0.94. The significance of these values is
two-fold. First, the change from 0.42 to 0.94 observed in the Pearson value when
Gh and Prl are excluded demonstrates the dominance of these two transcripts in
the transcriptomes of the somatotropes and lactotropes, with Gh and Prl reads
totaling approximately 25-33% of the mRNA reads in both cell types. Second, the
Pearson value of 0.94 after exclusion of Gh and Prl highlights the overall
similarity of the transcriptomes of these two cell types, except for their hormone
expression levels. This overall similarity at the transcriptomic level is consistent
with a close developmental relationship of these two cell types and suggests that
the somatotrope and lactotrope identities are likely to be driven and maintained
by a limited number of lineage-enriched factors2,20,52.
A specific issue that could be directly addressed from these data was
whether the structure of Pou1f1 in the two lineages might differ. The
transcriptome data demonstrated that the structure of the Pou1f1 mRNA is
identical in the two pools. These data effectively rule out a contribution by
alternative splicing of the Pou1f1 transcript53 and generation of lineage-specific
Pou1f1 isoforms to cell type specific functions of Pou1f1 (Fig. 3C). These
findings further highlight the importance of additional factors in driving
somatotrope and lactotrope specificity.
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Genes that surpassed a threshold of a Log2 fold change of 2 (Fig. 3B,
highlighted in red) were further filtered by significance (p-value <0.05) and
expression level to remove genes that are expressed at low levels and not
consistently enriched across all replicates. This differential expression analysis
yielded approximately 300 lineage enriched genes for each cell type. Using gene
ontology (GO) terms to guide the filtering of these 300 lineage enriched genes
produced a list of 24 differentially expressed genes with annotated transcription
factor activity (Fig. 3D). Thus, these transcriptomic analyses identified a set of
lineage-enriched transcription factors that may be important to the distinct
attributes of the somatotrope and lactotrope lineages.
Validation of transcription factor differential expression in somatotropes
and lactotropes by immunofluorescence analysis of primary pituitary cells.
In order to maximize the effectiveness of downstream studies on the
identified lineage-enriched transcription factors, we prioritized for further study a
subset of six lineage-enriched transcription factors -- 3 enriched in somatotropes
and 3 enriched in lactotropes-- that have functions reported in the literature that
are consistent with a role that could be related to pituitary gene regulation. We
next attempted to validate that each of the six transcription factors identified
enriched at the level of mRNA expression was also enriched at the level of
protein expression with the understanding that mRNA expression is not always
paralleled by protein production. We also wanted to determine the site of
accumulation of each of these proteins, as functional transcription factors would
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be expected to accumulate in the nucleus in order to impart transcriptional
controls.
Wild type adult female mouse pituitaries were disaggregated and
assessed by immunofluorescence microscopy (IF) for each of the six factors.
This was done in parallel with immunostaining for GH and PRL proteins in order
to mark somatotropes and lactotropes. The first factor to be studied was NUPR1,
a somatotrope-enriched factor chosen based on its role in a defined pituitary cell
differentiation process centered on the gonadotrope lineage43,54. NUPR1 was
enriched in the nuclei of somatotrope (GH+) cells, consistent with the enrichment
of the respective mRNA in the GFP+ cells (Fig. 4A). Of note, NUPR1, while
enriched in somatotropes vs. lactotropes, was also detected in additional pituitary
cells that are both GH and PRL negative. This observation is consistent with
reports that NUPR1 plays a role in the development gonadotropes 54.
A second somatotrope-enriched factor, RXRG, was selected for study due
to the stimulating effects of its ligand, retinoic acid, on growth hormone
production, as well as on its reported heterodimerization with the thyroid
hormone receptor, which is reported to bind at the Gh promoter55-58. RXRG
protein was also observed to be enriched in the nuclei of somatotrope cells,
identifying it as a gene of interest for further study (Fig. 4B). The third
somatotrope candidate factor, PPARG, has been shown in previous studies to be
frequently expressed in GH secreting pituitary adenomas, suggesting a role in
regulating the somatotrope lineage59. Immunofluorescence microscopy of
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PPARG protein revealed that it was enriched in somatotropes as expected (Fig.
4C), but was also present in 48% of lactotropes (detailed cell counts for all
immunofluorescence studies are available in Table 1). Therefore, while Pparg
may have a role in the regulation of these lineages, we excluded Pparg from
further study and focused on Nupr1 and Rxrg due to their more clearly defined
somatotrope enrichment. These studies thus confirmed that 2 of the 3 identified
somatotrope-enriched factors are appropriately expressed in primary
somatotrope cells, and thus these factors were selected for further studies.
IF studies were next carried out on the three transcription factors whose
mRNAs were enriched in lactotropes. Among the candidate transcription factors
selected from the lactotrope cell population, NR4A2 has been demonstrated to
positively regulate transcription of the prolactin gene in extra-pituitary (lymphoid)
tissue, making it a gene of interest for its potential role in the regulation of the
lactotrope lineage60. The NR4A2 protein was enriched in the nuclei of lactotrope
(PRL+) cells (Fig. 4D), consistent with transcriptomic data. POU4F1, a member
of the POU family of transcription factors, was selected for study due to its role in
stimulating aggressive proliferation of pituitary adenomas61, and on its multiple
regulatory roles in development throughout the neuroendocrine system 7,62. We
observed that the POU4F1 protein was also enriched in the nuclei of lactotrope
cells, suggesting a potential for regulating the lactotrope lineage (Fig. 4E). Lastly,
TBX19 was selected for study because it is known to be crucial for pituitary
development and establishment of cellular differentiation in the anterior lobe and
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intermediate lobe in pituitary, with its primary known function being in regulating
the corticotrope lineage where it has been reported to be specifically
expressed63-65. Immunofluorescence microscopy revealed TBX19 protein in both
somatotropes and lactotropes, as well as in additional cell types that were not
further characterized (Fig. 4F). Thus, while Tbx19 might be of interest to the
regulation of lactotropes, we chose to drop it from our initial studies.
The IF studies identified four factors that were enriched in the nuclei of the
appropriate cell types: Nupr1, Rxrg, Nr4a2, and Pou4f1. Each of these four
factors demonstrated robust cell type enrichment at the mRNA and protein
levels, and demonstrated restriction to the nucleus. All of these observations are
consistent with their identification as lineage-enriched transcription factors in our
transcriptomic analyses. In conclusion, the immunofluorescence microscopy
studies of these four transcription factors validated the RNA-seq data generated
from primary somatotropes and lactotropes, and suggested that they may play a
role in somatotrope vs. lactotrope differentiation and/or specification of cellular
function.
Discussion
The establishment and maintenance of cell lineages within the anterior
pituitary represents a robust model of cell type specification 66,67. Delineating the
controls of the relevant pathways is critical to understanding normal and
pathologic pathways of pituitary functions as they relate to mammalian growth,
reproduction, stress response and metabolic functions. Identification of these
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pathways and their driving factors has the potential to provide novel targets for
diagnosis and therapy of abnormalities in hormone expression and function. As
an illustration of the potential benefits of improving understanding of these
lineages, the majority of prolactin secreting adenomas (prolactinomas) can be
treated medically rather than surgically by administration of dopamine agonists,
which bind to the DRD2 receptor and selectively inhibit lactotrope proliferation
and prolactin expression68. While this medical approach is widely employed in
clinical practice, a subset of prolactinomas do not respond to such therapy,
necessitating more invasive treatment due to the lack of known treatment targets
beyond the dopamine receptor. This gap in therapeutic efficacy highlights the
unmet need for better understanding these lineages and their underlying control
pathways69,70.
Extensive genetic studies in humans and mice have identified a number of
transcription factors that are essential for pituitary development and function in
the mammalian embryo. However, the identification and functional
characterization of factors that drive specification of the two primary lineages in
the anterior pituitary, the somatotropes and lactotropes, remains remarkably
limited2,43. According to current models, these lineages are hypothesized to
diverge from a common “somatolactotrope” precursor late in embryogenesis
(Fig. 1)2, although there is some evidence that a subset of lactotropes emerge
directly from somatotrope cells15. What is clear is that the pathways of cell
expansion and terminal differentiation that generate and maintain both
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somatotropes and lactotropes are dependent on the functions of the pituitary
master regulatory transcription factor, POU1F1. Although both of these lineages
depend on POU1F1 for their expansion and hormonal expression, it is evident
that additional factors must be involved in driving their functional divergence.
Factors identified in limited previous studies (see Chapter I) failed to exhibit
evidence of differential expression in our transcriptome analyses, highlighting the
challenges in selecting targets for further study without transcriptomic data for
isolated cell populations. The identification of such factors has also been
hampered in most studies due to their focus on the limited number of known
marker proteins or their encoding mRNAs. Thus, substantial advances will
depend on the use of more broad based discovery approaches.
In the initial phase of this thesis project, we established and compared the
transcriptomes of the somatotrope and lactotrope lineages isolated from the adult
mouse pituitary. These transcriptomic databases were derived by RNA-seq
analysis of cell populations isolated on the basis of fluorescent markers (GFP
and DsRed) driven by the Gh or the Prl transcription regulatory elements. The
validity of this approach was supported by a high level of enrichment of the
expected hormone mRNAs in each RNA-seq data set (Fig. 2C) and by the
enrichment of other known marker genes (Fig. 3A). Analysis of these data sets
allowed us to arrive at several fundamental observations. First, the direct
comparison of the transcriptomes of the two cell types, after removing Gh and Prl
from the analysis, revealed a striking overall correlation (Pearson = 0.94; Fig.
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3B). This high level of concordance affirms the close developmental and
functional relationships of these two lineages. The second observation is that the
two cell populations partially overlap in the expression of their key hormone
genes, Gh and Prl. While we find that Gh mRNA is appropriately enriched in the
GFP+ cell pool and Prl mRNA is appropriately enriched in the DsRed+ cell pool
(Fig. 3A), there are appreciable levels of Gh mRNA in the lactotrope (DsRed+)
population and a reciprocal representation of Prl mRNA in the somatotrope
(GFP+) population (Fig. 2C). While it is likely that small amounts of crosscontamination inherent in techniques such as FACS contribute in part to this
result, these data are consistent with the established observations that both
genes are activated by Pou1f1, which is expressed in both somatotropes and
lactotropes, raising the possibility of a basal level of transcription of the reciprocal
hormone in each lineage. This observation that a detectable amount of Gh and
Prl mRNAs are produced in the reciprocal lineages supports a model in which
somatotropes and lactotropes repress but do not entirely silence the Prl and Gh
genes, respectively. The third observation is that, despite the overall similarities
in the transcriptomes of the somatotropes and lactotropes noted above, a set of
approximately 300 genes, including multiple transcription factors, is significantly
enriched in each lineage. Taken together, these observations suggest that the
transcriptomic differences between the somatotrope and lactotrope lineages are
quite limited, yet clearly crucial; differential expression of a small set of genes is
able to drive noteworthy differences in cell identity and function.
24

The transcriptome data generated in the present study provide insights
into aspects of the somatotrope and lactotrope lineages beyond lineage-enriched
transcription factors. While the scope of the present study centers on these
transcription factors, other aspects of the transcriptomes of the somatotropes and
lactotropes may be of interest for future studies. One post-transcriptional
mechanism that has been hypothesized to contribute to differential regulation in
the somatotrope and lactotrope lineages is alternative splicing of Pou1f1. There
are two known isoforms of Pou1f1: the major isoform, known simply as Pou1f1,
and the alternative isoform Pou1f1β, formed by alternative splicing extending the
second exon, which has been previously suggested to have a repressive function
in regulating gene expression in the POU1F1-dependent lineages of the
pituitary53,71,72. Our data reveals that the levels of Pou1f1 mRNA and its exonic
structure (Fig. 3C) are equivalent in the somatotrope and lactotrope populations.
This observation supports the hypothesis that the divergence of lactotropes and
somatotropes is based on the functions of a set of somatotrope and lactotrope
specific factors that may work independently, or in conjunction with POU1F1,
rather than differences in the levels or structure of POU1F1 itself.
Further analysis of the genes that are enriched in somatotropes and
lactotropes was performed. Enriched Gene Ontology (GO) terms were
determined by running the Gene Ontology Consortium’s enrichment analysis tool
on the approximately 300 statistically enriched genes in both somatotropes and
lactotropes (Supplemental Tables 1 and 2, respectively). While many of the
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enriched GO terms do not have obvious links to somatotrope/lactotrope function,
“hormone activity” is a significantly enriched GO term, consistent with the primary
function of these cell types. However, many of the genes included in the
enrichment of this term are previously known genes such as Gh itself and Ghrhr.
Thus, the utility of GO term analysis in identifying novel genes involved in the
somatotrope and lactotrope lineages is limited due to the reliance of GO term
analysis on existing knowledge about the roles of many genes, and the narrow
set of genes known to be crucial to the regulation of each cell type. We thus
focused our later analyses of this transcriptomic data on more targeted
approaches rather than broad GO term analyses.
Among the sets of differentially expressed genes, we identified a set of
lineage-enriched transcription factors. Of note, most of these factors have not
been previously linked to somatotrope or lactotrope identity and function (Fig.
3D). Six differentially expressed transcription factors were chosen for detailed
study. This selection was based on reports of these six factors having
mechanisms of action or functions that would be consistent with their suspected
roles in the somatotrope and lactotrope lineages. In an initial screen,
immunofluorescence analysis confirmed that four of these six factors were
robustly enriched in the nuclei of the cell type predicted by their differential
mRNA expression (Fig. 4). The remaining two factors were not similarly enriched
and were therefore eliminated from further study. The functional impacts of the
four validated transcription factors are explored in Chapter III. Together, these
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transcriptomic analyses not only identify candidate regulators of both the
somatotrope and lactotrope lineages, but provide a robust data set for further
probing the transcriptomic differences between these two cell lineages.
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Figures and legends
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Figure 2. Fluorescence activated cell sorting (FACS) of primary somatotropes and lactotropes from the mouse
pituitary. A. Schematic of the two transgenes used for selective isolation of somatotropes and lactotropes. B.
Representative FACS of pituitary cells harvested from cosGH-eGFP/rPrl-DsRedcyto compound transgenic mice. The X

axis represents GFP expression and the Y axis represents DsRed expression. Gating used for sorting is represented by
rectangles encompassing the sorted populations. C. Relative expression levels of mRNAs encoding the full array of
anterior pituitary hormones in the whole pituitary, and from the two FACS populations. Normalized reads (FPKM) are
shown for the anterior pituitary hormone genes in total pituitary (left), FACS sorted GFP + cells (middle), and FACS sorted
DsRed+ cells (right). All samples used for transcriptomic analyses were generated from 6-8-week old virgin female mice.
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Figure 3. RNA-seq analyses of flow sorted GFP+ and DsRed+ cell populations reveal subsets of lineage-enriched
transcription factors. A. Enrichment (Log2 fold change) of mRNAs in the GFP+ and DsRed+ populations encoding

defined markers for somatotropes (green), lactotropes (red), and for markers shared between somatotropes and
lactotropes (blue). The designation of each respective marker gene is noted at the bottom of the figure. A positive value
on the Y-axis indicates enrichment in the GFP+ population while a negative value indicates enrichment in the DsRed +
population. Significance values relate to the enrichment in mRNA expression between the two flow sorted populations. *
Indicates p-value of less than 0.05, ** indicates p-value of less than 0.01, n.s. indicates not significant. B. Correlation plot
of the RNA-seq analysis GFP+ cells vs. DsRed+ cells. The Log2 FPKM values for all mRNAs in the GFP+ (x-axis) and
DsRed+ (y-axis) samples were plotted, and mRNAs surpassing a threshold of 4-fold enrichment or greater were
highlighted in red. These enriched mRNAs were then further filtered to remove low expressers, leaving only genes that
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were robustly expressed and significantly enriched (p < 0.05). The positions of Gh and Prl are noted on this plot. C.
Representative Sashimi plot track showing raw mapped mRNA reads at the Pou1f1 locus in GFP+ and DsRed+ cell
populations. The identity of the two Sashimi plots indicates identical splicing patterns of the Pou1f1 transcript in
somatotropes and lactotropes, in accordance with analysis performed using TopHat2 (see Methods). D. List of
transcription factors enriched in GFP+ vs. DsRed+ cell populations were identified by taking the GFP/DsRed specific
genes identified by differential expression analysis and using PANTHER to identify genes with known GO terms for
transcription factor activity.
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Figure 4. Immunofluorescence microscopy validated cell-type specificity of expression for a subset of lineage
enriched transcription factors. Cells disaggregated from wild type pituitaries (female) were stained for each of six

transcription factors whose mRNAs were enriched in the GFP+ cell population (A-C) and the DsRed+ cell population (D-F)
(as in Fig. 3D). Each transcription factor is stained in green, and cells were co-stained red with antibodies to identify GH
or PRL as a means of identifying somatotropes and lactotropes, respectively. A. NUPR1, B. RXRG, C. PPARG. D.
NR4A2. E. POU4F1. F. TBX19. All cells were stained with DAPI (blue) to mark nuclei. Scale bars = 5 μm.
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Tables

Table 1. Cell counts for immunofluorescence assays. Cell counts for
immunofluorescence microscopy analyses of selected transcription factors.
Columns list the number of GH+ or PRL+ cells examined (200 GH+ and 200 PRL+
cells counted per study) expressing the given transcription factor, as well as the
percentage of total somatotropes/lactotropes observed expressing the protein in
parentheses.
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Supplemental Data

Supplemental Figure 1. Schematic of GH-GFP transgene and modified version
of transgene without the growth hormone signal peptide. The previously
described GH-GFP transgene (top) produces somatotrope-specific GFP
expression, but the presence of the growth hormone signal peptide (first 24
amino acids of the GH protein) causes GFP to be secreted as growth hormone
is, leading to some somatotropes having relatively low GFP levels. By truncating
the beginning of exon 2 (bottom panel), the signal peptide was reduced from its
full 24 amino acids to only 8 amino acids, ablating its function and causing the
GFP protein produced from this transgene to accumulate in the cytoplasm of
somatotropes. No other modifications were made to the transgene.
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Supplemental Figure 2. Immunofluorescence microscopy of GH-eGFP pituitary
cells demonstrating that GFP is selectively expressed in somatotropes.
Pituitaries from GH-eGFP mice were disaggregated and co-stained for DAPI,
GFP, GH, and PRL, as indicated in each frame. The red arrows indicate three
GFP+ cells which are also GH+. The white arrow indicates a PRL+ cell which is
negative for GFP and GH. The merge frame combines DAPI along with GFP
(green), GH (red), and PRL (white). A total of 200 somatotropes and 200
lactotropes (identified by the expression of GH or PRL, respectively) were
assayed for GFP expression. Out of 200 somatotropes, 184 (92%) were GFP
positive. Out of 200 lactotropes, 2 (1%) were GFP positive. These data
demonstrate robust somatotrope specificity for the GH-eGFP line. Scale bar, 5
um.
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Supplemental Table 1. Total read counts for GFP and DsRed mRNAs in each
FACS-sorted sample used for RNA-seq analysis.
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GO molecular function complete

Raw Pvalue

FDR

carbohydrate:cation symporter activity (GO:0005402)

3.18E-04

lipopolysaccharide binding (GO:0001530)

5.92E-05

carbohydrate transmembrane transporter activity (GO:0015144)

1.87E-04

nuclear receptor activity (GO:0004879)

4.14E-05

transcription factor activity, direct ligand regulated sequence-specific DNA
binding (GO:0098531)
voltage-gated potassium channel activity (GO:0005249)

4.14E-05

4.66E02
1.04E02
2.93E02
7.85E03
7.54E03

steroid hormone receptor activity (GO:0003707)

6.92E-05

potassium channel activity (GO:0005267)

4.03E-07

voltage-gated cation channel activity (GO:0022843)

9.57E-07

potassium ion transmembrane transporter activity (GO:0015079)

3.69E-07

voltage-gated channel activity (GO:0022832)

9.35E-06

voltage-gated ion channel activity (GO:0005244)

9.35E-06

heparin binding (GO:0008201)

1.22E-04

glycosaminoglycan binding (GO:0005539)

1.35E-05

monovalent inorganic cation transmembrane transporter activity
(GO:0015077)
ion gated channel activity (GO:0022839)

3.49E-07

gated channel activity (GO:0022836)

4.25E-06

secondary active transmembrane transporter activity (GO:0015291)

2.26E-04

cation channel activity (GO:0005261)

1.57E-05

ion channel activity (GO:0005216)

1.82E-06

passive transmembrane transporter activity (GO:0022803)

8.62E-07

channel activity (GO:0015267)

8.62E-07

substrate-specific channel activity (GO:0022838)

2.53E-06

metal ion transmembrane transporter activity (GO:0046873)

1.23E-05

cation transmembrane transporter activity (GO:0008324)

4.53E-07

inorganic cation transmembrane transporter activity (GO:0022890)

2.93E-06

ion transmembrane transporter activity (GO:0015075)

4.41E-08

inorganic molecular entity transmembrane transporter activity (GO:0015318)

2.64E-07

lipid binding (GO:0008289)

2.46E-05

transmembrane transporter activity (GO:0022857)

8.99E-07

transporter activity (GO:0005215)

9.46E-06

3.44E-07

3.19E-06

5.21E04
1.16E02
3.06E04
3.96E04
3.36E04
2.50E03
2.36E03
1.98E02
2.93E03
3.97E04
9.67E04
1.21E03
3.43E02
3.24E03
6.88E04
4.90E04
4.36E04
8.85E04
2.79E03
2.94E04
9.51E04
2.01E04
6.01E04
4.87E03
4.09E04
2.27E03

Supplemental Table 2. Molecular function (GO ontology) terms enriched in
somatotrope genes.
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GO molecular function complete
G-protein coupled nucleotide receptor activity (GO:0001608)
G-protein coupled purinergic nucleotide receptor activity
(GO:0045028)
G-protein coupled photoreceptor activity (GO:0008020)
chemokine receptor activity (GO:0004950)
G-protein coupled chemoattractant receptor activity
(GO:0001637)
C-C chemokine binding (GO:0019957)
purinergic nucleotide receptor activity (GO:0001614)
nucleotide receptor activity (GO:0016502)
C-C chemokine receptor activity (GO:0016493)
chemokine activity (GO:0008009)
purinergic receptor activity (GO:0035586)
chemokine binding (GO:0019956)
transmitter-gated ion channel activity involved in regulation of
postsynaptic membrane potential (GO:1904315)
chemokine receptor binding (GO:0042379)
neurotransmitter receptor activity involved in regulation of
postsynaptic membrane potential (GO:0099529)
postsynaptic neurotransmitter receptor activity (GO:0098960)
transmitter-gated channel activity (GO:0022835)
transmitter-gated ion channel activity (GO:0022824)
CCR chemokine receptor binding (GO:0048020)
G-protein coupled peptide receptor activity (GO:0008528)
peptide receptor activity (GO:0001653)
extracellular ligand-gated ion channel activity (GO:0005230)
neurotransmitter receptor activity (GO:0030594)
ligand-gated channel activity (GO:0022834)
ligand-gated ion channel activity (GO:0015276)
ligand-gated cation channel activity (GO:0099094)
hormone binding (GO:0042562)
cytokine activity (GO:0005125)
carbohydrate binding (GO:0030246)
G-protein coupled receptor binding (GO:0001664)
cytokine receptor binding (GO:0005126)
ion gated channel activity (GO:0022839)
gated channel activity (GO:0022836)
G-protein coupled receptor activity (GO:0004930)
ion channel activity (GO:0005216)
passive transmembrane transporter activity (GO:0022803)
channel activity (GO:0015267)
substrate-specific channel activity (GO:0022838)
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Raw P-value

FDR

7.82E-06

1.78E-03

7.82E-06

1.69E-03

5.48E-04

4.98E-02

3.64E-07

2.36E-04

3.64E-07

2.07E-04

3.64E-07

1.84E-04

8.71E-06

1.80E-03

8.71E-06

1.72E-03

2.64E-06

9.24E-04

4.64E-10

7.03E-07

3.40E-06

1.10E-03

2.03E-06

7.68E-04

2.30E-05

3.48E-03

6.74E-09

6.13E-06

2.75E-05

3.79E-03

3.89E-05

4.78E-03

1.05E-05

1.90E-03

1.05E-05

1.83E-03

1.14E-04

1.26E-02

2.40E-10

1.09E-06

3.96E-10

9.00E-07

1.12E-04

1.27E-02

1.43E-05

2.32E-03

6.24E-06

1.77E-03

6.24E-06

1.67E-03

3.17E-04

3.07E-02

2.36E-04

2.39E-02

4.39E-07

2.00E-04

5.92E-07

2.45E-04

2.84E-05

3.80E-03

9.83E-06

1.86E-03

3.63E-05

4.59E-03

5.57E-05

6.49E-03

8.10E-10

9.21E-07

1.27E-05

2.15E-03

7.63E-06

1.93E-03

7.63E-06

1.83E-03

1.87E-05

2.94E-03

cation channel activity (GO:0005261)
receptor ligand activity (GO:0048018)
receptor regulator activity (GO:0030545)
signaling receptor activity (GO:0038023)
molecular transducer activity (GO:0060089)
transmembrane signaling receptor activity (GO:0004888)
protein binding (GO:0005515)
binding (GO:0005488)
molecular_function (GO:0003674)
Unclassified (UNCLASSIFIED)
RNA binding (GO:0003723)
olfactory receptor activity (GO:0004984)
odorant binding (GO:0005549)

5.55E-04

4.95E-02

4.14E-05

4.95E-03

2.47E-05

3.51E-03

2.42E-05

3.54E-03

3.19E-05

4.15E-03

1.27E-04

1.37E-02

4.59E-04

4.26E-02

4.80E-06

1.46E-03

2.12E-04

2.19E-02

2.12E-04

2.25E-02

2.61E-04

2.58E-02

1.02E-07

7.70E-05

3.27E-04

3.10E-02

Supplemental Table 3. Molecular function (GO ontology) terms enriched in
lactotrope genes
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CHAPTER III: A SET OF CELL TYPE-ENRICHED
TRANSCRIPTION FACTORS IMPACTS EXPRESSION OF
LANDMARK PITUITARY GENES
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Introduction
Transcription factors may act through a variety of mechanisms and can
exert either activating or repressing effects. Transcription factors enriched in
either the somatotrope or lactotrope cell populations may have roles in
enhancing the expression of landmark genes within their cell lineage or they may
play a role in repressing genes of the reciprocal lineage. For example, a
transcription factor enriched in somatotropes may have a role in enhancing Gh
expression or in repressing Prl expression. Elucidating these functional impacts
as well as their mechanistic bases is crucial to understanding the role that an
identified transcription factor has in regulating the somatotrope or lactotrope
lineages.
Having identified and validated a set of four candidate transcriptions—two
expressed in somatotropes and two expressed in lactotropes—we next wanted to
assess their roles in regulating their respective cell types. Here, we utilize a set of
murine pituitary-derived cell line models to assay the functional impacts of each
of the candidate transcription factors on known landmark genes in both the
somatotrope and lactotrope lineages. These transcription factors were also
assessed for occupancy at chromatin sites encompassing the Gh and Prl gene
promoters. Mechanistic studies reveal that one of the lactotrope-enriched factors
binds adjacent to POU1F1 at the Prl gene promoter and synergizes with
POU1F1 in stimulation of Prl gene transcription by enhancing the release of Pol II
from the Prl promoter. In contrast, a second factor was found to repress Prl
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expression in somatotropes through an indirect mechanism. These studies
highlight and begin to define the variety of mechanisms that underlie lineage
specificity in the mammalian pituitary.
Results
Functional assessment of candidate transcription factors: impacts on
somatotrope and lactotrope gene expression in cell culture
To determine the functional impact of the four candidate factors on
somatotrope and lactotrope identity, we expressed each factor in a murine
pituitary-derived cell line, Pit-1/Triple28. Pit-1/Triple cells, isolated by T-antigen
immortalization of mouse pituitary cells, express POU1F1 (also referred to as
PIT-16) as well as the three POU1F1 dependent hormones: GH, PRL, and TSH.
The Pit-1/Triple cells express robust levels of Pou1f1 and express each of the
Gh, Prl, and Tshb mRNAs at levels substantially lower than those detected in
whole adult mouse pituitary28. On the basis of this profile of gene expression, we
have proposed that these Pit-1/Triple cells may represent cells at an early stage
in pituitary development, immediately following the activation of Pou1f1 but prior
to terminal differentiation of the individual hormone expressing lineages 28
(corresponding to the “Triple positive, e14.5” cells noted in Fig. 1).
Transcriptomic analyses of the Pit-1/Triple cells (unpublished data) revealed that
each of the four candidate transcription factors identified and validated in
Chapter II is either not expressed or expressed at low levels. We hypothesized
that forced expression of each of the factors would have a specific impact on
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genes that in some manner define lactotrope or somatotrope cell identity. To test
this hypothesis, each candidate factor was ectopically expressed in Pit-1/Triple
cells from a bi-cistronic expression vector containing the transcription factor ORF
and a GFP ORF behind an internal ribosome entry site (IRES) (see details in
Methods). 48 hours post transfection, GFP+ Pit-1/Triple cells were isolated by
FACS. RNA was isolated and assayed by qRT-PCR to assess impacts of each
factor on the expression of somatotrope and lactotrope marker genes. The
expression of each target gene was compared to the corresponding mRNA levels
in GFP+ cells isolated from a control transfection with an empty (GFP-only)
vector.
A panel of five lineage marker genes was assayed in each qRT-PCR
assay. Gh and the growth hormone releasing hormone receptor (Ghrhr) were
assayed as markers of the somatotrope lineage while Prl and the dopamine
receptor (Drd2) were assayed as markers of the lactotrope lineage. Pou1f1 was
included in the panel of assayed genes as a gene that is common to both
lineages. This panel of genes, while not encompassing a comprehensive set of
somatotrope/lactotrope markers, includes the most prominent known markers
and thus serves as a useful metric for assaying changes in the expression of
genes crucial to these two lineages.
Ectopic expression of the somatotrope candidate factor, Nupr1, in the Pit1/Triple cells caused a significant repression of both Prl and Drd2 while failing to
impact on expression of Gh or Ghrhr (Fig. 5A). This impact of Nupr1 would be
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consistent with a role for this somatotrope-enriched factor in selectively
repressing the expression of lactotrope genes in the somatotrope lineage.
Expression of Rxrg failed to impact the expression of any of the assayed genes
(Fig. 5B), even in the presence of its ligand, retinoic acid (Supplemental Figure
3)73,74, and so Rxrg was excluded from further study. Expression of the lactotrope
candidate factors, Nr4a2 and Pou4f1, both resulted in a significant increase in Prl
expression and while leaving the expression of the other assayed genes
unchanged (Fig. 5C, D). These data are consistent with these two lactotropeenriched factors serving to enhance the expression of Prl in the lactotrope
lineage. In sum, the data from these cell transfection studies support potential
reciprocal roles for three lineage-enriched factors; activating lactotrope specific
genes linked to lactotrope identity (Nr4a2 and Pou4f1), and repressing lactotrope
specific genes to maintain somatotrope identity (Nupr1).
Characterization of transcriptional regulatory mechanisms at the Prl
promoter of the lineage-enriched transcription factors
The mechanism of action by which a regulatory factor affects the
transcription of a gene can be direct or indirect. One indication of direct action on
transcription is the occupancy of the factor at regulatory elements linked to the
gene of interest. Nr4a2 and Pou4f1 both enhance Prl expression when
expressed in Pit-1/Triple cells (Fig. 5C, D), raising the possibility of direct binding
at the Prl promoter. Two binding sites for both NR4A2 and POU4F1 are predicted
within a 250 bp region of the Prl promoter by JASPAR analysis75, and these sites
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are intermingled with 4 known POU1F1 binding sites21,75. Of particular interest
was the observation that one of the NR4A2 predicted binding sites is located
immediately adjacent to the POU1F1 binding site most proximal to the Prl start
codon (Fig. 6A). This close positioning of the POU1F1 and NR4A2 binding sites
raises the possibility that NR4A2 and POU1F1 interact at the Prl promoter. Pit1/Triple cells expressing recombinant NR4A2 or POU4F1 were generated and
enriched by FACS (as above), and chromatin was assayed for factor occupancy
at the Prl promoter. The MyoD promoter was assayed as a control for nonspecific binding and the Gh promoter was assayed as a specificity control.
Additional sites 500 bp upstream and downstream of the Prl promoter were also
assayed to confirm that any binding at the promoter was promoter-specific. The
NR4A2 ChIP revealed significant and specific binding at the Prl promoter (Fig.
6B), while a parallel ChIP assay for POU4F1 failed to reveal evidence of
significant binding in this region. POU4F1 binding to its known autoregulatory
element76 confirmed the efficacy of the POU4F1 ChIP study. (Fig. 6C, D). In
order to confirm that NR4A2 binds to the Prl promoter in vivo, NR4A2 ChIP was
performed on chromatin isolated from FACS-sorted mouse lactotropes (Fig. 6E).
The data from the analysis of these primary mouse cells demonstrated selective
in vivo binding of NR4A2 at the Prl promoter. Thus, these ChIP studies along
with the preceding gene expression assays reveal that NR4A2 is recruited to the
Prl promoter and enhances Prl gene expression. In contrast, POU4F1 does not
bind the Prl promoter and thus the enhancement of Prl expression observed in
the Pit-1/Triple cell transfection study may reflect its binding to an as yet
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uncharacterized regulatory element beyond the proximal Prl promoter, or through
an indirect mechanism.
The lactotrope-enriched transcription factor, NR4A2, acts in conjunction
with POU1F1 to enhance Prl gene expression.
The binding of NR4A2 adjacent to a POU1F1 binding site within the Prl
promoter suggested a model in which NR4A2 works in concert with POU1F1 to
support Prl gene expression. This model was tested by transfections of the two
factors either alone or in combination into the Pit-1/0 cell line28. Pit-1/0 cells,
generated by SV40 T-antigen mediated transformation of mouse pituitary cells
(as with the Pit-1/Triple cells), model an early stage of anterior pituitary
development in which Pou1f1 is activated, but not yet expressed at significant
levels, and in which none of the three POU1F1-dependent hormone genes (Gh,
Prl, and Tshb) have yet been activated (corresponding to the “Pou1f1+ cell,
e13.5”; Fig. 1)28. Pit-1/0 cells were transfected with plasmids encoding either
Pou1f1 or Nr4a2 alone, or with a 1:1 mix of the two expression vectors. Cells
transfected with the Pou1f1 expression vector alone exhibited a 4-fold increase in
Prl expression over a vector control (Fig. 6F). Although a parallel transfection
with Nr4a2 plasmid alone displayed no activation of Prl expression, cotransfection of Nr4a2 plasmid with the Pou1f1 plasmid stimulated Prl expression
8-fold over the vector control. There was no apparent impact of the factor
transfections, either alone or in combination, on the other marker genes in the
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assay panel. These data suggest that NR4A2 requires the presence of POU1F1
to enhance expression of the Prl gene.

NR4A2 fails to enhance POU1F1 occupancy at the Prl promoter or
enhance the presence of activating chromatin marks
What is the mechanism by which NR4A2 enhances POU1F1 actions at
the Prl promoter? One potential mechanism is by facilitating recruitment of
POU1F1 to the Prl promoter. To test this hypothesis, POU1F1 occupancy was
assayed by ChIP in Pit-1/Triple cells expressing exogenous NR4A2 and
compared to POU1F1 occupancy in Pit-1/Triple cells not expressing NR4A2 (Fig.
7). The ChIP was performed using a POU1F1 antibody generated in the lab and
validated by demonstrating specific detection of POU1F1 (Supplemental Figure
4). This experiment revealed no enhancement of POU1F1 occupancy at the Prl
promoter in the presence of NR4A2. Thus, the functional interaction of NR4A2
with POU1F1 at the Prl promoter does not rely on increasing POU1F1
recruitment to the Prl promoter.
Having observed that NR4A2 binds the Prl promoter adjacent to a known
POU1F1 binding site and that NR4A2 does not enhance the binding of POU1F1,
we next hypothesized that NR4A2 may play a role in histone modification at the
Prl promoter prior to transcription. Histone acetylation constitutes an early step
towards initiating transcription77,78, and histone 3 lysine 27 (H3K27) acetylation
as well as histone 3 lysine 4 (H3K4) tri-methylation have been identified as
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promoter marks that strongly correlate with active transcription79-81. To test our
hypothesis, we assayed changes in H3K27 acetylation and H3K4 tri-methylation
at both the Gh and Prl promoters in Pit-1/0 cells transfected with Pou1f1 or Nr4a2
alone, or transfected with a 1:1 mix of both factors. Pit-1/0 cells were used in this
assay because the Gh, Prl, and Pou1f1 genes are inactive, making these cells a
useful model for detecting epigenetic modifications at these loci that track with
the process of transcriptional activation. Transfection with Pou1f1 alone caused a
significant increase in H3K27 acetylation at both the Gh and Prl promoters,
consistent with the known roles of POU1F1 in activating both of these genes
(Fig. 8A). In contrast, transfection with Nr4a2 alone did not cause an increase in
H3K27 acetylation over an empty vector control, and cells transfected with both
Pou1f1 and Nr4a2 had levels of H3K27 acetylation similar to those of cells
transfected with Pou1f1 alone. A similar effect was observed when assaying
changes in H3K4me3 levels (Fig. 8B) with expression of Pou1f1 alone causing
an increase in H3K4me3 levels at both the Gh and Prl promoters while the
addition of Nr4a2 caused no significant change in H3K4 tri-methylation over the
level observed in the presence of Pou1f1 alone. These data indicate that
POU1F1 is sufficient to recruit histone acetylases and methylases to impart
activating modifications at both the Gh and Prl promoters. The data further
suggest that these activating modifications imparted by POU1F1 are not
sufficient for selective transcriptional activation of Gh vs. Prl, as Pou1f1
selectively increases levels of Prl but not Gh mRNA in the Pou1f1 transfected Pit1/0 cells (Fig. 6F). Finally, the data indicate that NR4A2 appears to enhance Prl
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expression via a mechanism unrelated to any augmentation in H3K27 acetylation
or H3K4 tri-methylation over that imparted by POU1F1. Taken together, these
data lead us to conclude that the lactotrope-enriched factor, NR4A2, binds
adjacent to POU1F1 at the Prl promoter and synergizes with POU1F1 to
enhance Prl gene expression through a mechanism that is unrelated to POU1F1
recruitment or to the augmentation of defined histone modifications.
NR4A2 binding at the Prl promoter is POU1F1 dependent
In our preceding studies we determined that NR4A2 and POU1F1 bind at
adjacent sites in the Prl gene promoter, that NR4A2 does not impact on POU1F1
occupancy at the Prl promoter, nor does it augment the levels of activating
modifications at the Prl promoter. We also demonstrated that Nr4a2 has no
impact on Prl gene expression in the absence of Pou1f1. These data could be
unified in a model in which POU1F1 initially binds to the Prl promoter and makes
the adjacent chromatin of the promoter accessible for NR4A2 binding. To
determine if NR4A2 binding at the Prl promoter is in fact POU1F1 dependent, we
transfected Pit-1/0 cells (which express neither Nr4a2 nor appreciable levels of
Pou1f1) with combinations of plasmids expressing Nr4a2 and Pou1f1. These
cells were harvested, chromatin isolated and the occupancy of NR4A2 at the Prl
promoter was assessed by NR4A2 ChIP. NR4A2 protein binding to the Prl
promoter was only observed in cells that co-expressed Nr4a2 and Pou1f1. There
was no evidence of binding of NR4A2 in cells containing Nr4a2 but lacking
Pou1f1 (Fig. 9). Thus POU1F1 plays an essential role in facilitating the binding of
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NR4A2 at the Prl promoter. These data, in conjunction with the prior observation
that Nr4a2 can only enhance Prl expression in the presence of Pou1f1 (Fig. 6F),
suggest a model in which NR4A2 binds at the Prl promoter in a POU1F1dependent manner and enhances Prl expression in conjunction with, and fully
dependent on the co-binding of POU1F1. This conclusion raises the mechanistic
question of how NR4A2 acts to enhance the action of POU1F1 at the Prl
promoter.
NR4A2 enhances the release of RNA polymerase II from the Prl promoter,
increasing transcription
The observation that NR4A2 binding was selective to the Prl promoter vs.
the Gh promoter and that its functions were dependent on Pou1f1 raised the
possibility that it served to in some way potentiate Pou1f1 actions on Prl. Based
on the preceding data we hypothesized that NR4A2 may enhance Prl
transcriptional activity by augmenting in some manner the recruitment of RNA
polymerase II (Pol II) to the Prl promoter or by enhancing the actions of Pol II
once recruited. To initially test these models, we transfected Pit-1/0 cells with
plasmids that express Pou1f1 and Nr4a2 (see above and Methods) and assayed
Pol II occupancy at key regulatory elements of the Prl locus as well as regulatory
elements at the Gh and Pou1f1 loci (Fig. 10). This Pol II ChIP study produced
the noteworthy observation that Pol II recruitment to the Prl promoter is
dependent on the actions of Pou1f1 and that this recruitment to the Prl promoter
is not impacted to any extent by the co-expression of Nr4a2. Surprisingly,
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however, the ChIP analysis revealed that Nr4a2 robustly enhanced the presence
of Pol II within the Prl gene body (Fig. 10, “Prl downstream”). Together, these
data suggest that NR4A2 has an impact on Prl promoter function that is distal to
POU1F1 binding and distal to Pol II recruitment. One possible mechanistic model
that fits these findings is that NR4A2 plays a role in the release of Pol II from the
Prl promoter into the gene body.
The observation that NR4A2 may be involved in the release of Pol II from
the Prl promoter prompted us to hypothesize that NR4A2 plays a role in
recruiting Pol II release factors to the Prl promoter. The major release factor that
permits the release of Pol II from promoters is P-TEFb, composed of Cdk9 and
cyclin T182,83. To determine if NR4A2 enhances recruitment of P-TEFb to the Prl
promoter, we transfected Pit-1/0 cells with plasmids expressing Pou1f1 and
Nr4a2 and performed ChIP for the Cdk9 component of P-TEFb. The presence of
POU1F1 stimulated significant increases in Cdk9 occupancy at both the Gh and
Prl promoters, as well as a robust recruitment of Cdk9 to the auto-regulatory
Pou1f1 promoter9 (Fig. 11). Remarkably, however, there was no significant
increase in Cdk9 occupancy at the Prl promoter in cells co-expressing POU1F1
and NR4A2 as compared with POU1F1 alone. We conclude from these studies
that the selective stimulatory impact of NR4A2 on Pol II release from the Prl
promoter appears to act by a P-TEFb independent pathway. These data
establish a foundation for future studies that focus on identifying the components
and mechanism of Nr4a2-mediated Pol II release at the Prl promoter.
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Discussion
We have previously identified a set of transcription factors enriched in
either somatotropes or lactotropes (Chapter II). The four transcription factors
with appropriate localization and enrichment by immunofluorescence analysis
were subsequently assessed for functions relevant to lineage identity by
expression of the recombinant proteins in the Pit-1/Triple cell line. Our studies of
the somatotrope-enriched transcription factor, Nupr1, were highly informative.
Ectopic expression of Nupr1 in the Pit-1/Triple cells, caused a decrease in the
two most prominent lactotrope gene markers, Prl and Drd2. This action suggests
that the somatotrope factor Nupr1 exerts a repressive action on lactotrope
specific genes, an activity that could contribute to the maintenance of
somatotrope lineage identity (Fig. 5A). It is of note that Nupr1-/- mice have been
reported to be fertile and of normal size54. The normal size of these Nupr1-/- mice
is consistent with our observations that Nupr1 expression does not impact Gh
levels. Based on the repressive effect of Nupr1 on Prl expression in the Pit1/Triple cells, we would predict that Nupr1-/- mice will display elevated levels of
Prl expression. The observation that Nupr1-/- mice are fertile suggests that the
loss of Prl repression in somatotropes is not to an extent sufficient to result in
fertility problems. Such conclusions can be best addressed by in vivo condition
gene modification studies, as described in Chapter IV. Of further interest is our
observation that NUPR1 is expressed in approximately half (54%) of
somatolactotropes (Supplemental figure 5). These data suggest that NUPR1 is
not fully sufficient to repress Prl expression and that there are likely other factors
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involved in repressing Prl expression in the somatotrope lineage, either additively
or synergistically with NUPR1. Transcription factor binding site analyses did not
identify a putative binding site for NUPR1 within the Prl promoter, suggesting that
the mechanism of action may be indirect or may be dependent upon NUPR1
binding at a currently unknown Prl regulatory element. While the current study
did not identify a reciprocally-acting transcription factor in lactotropes that
represses somatotrope genes in lactotropes, it would be reasonable to
hypothesize that such factors exist and future studies will aim to identify them.
Expression of the second somatotrope-enriched factor, Rxrg, in Pit1/Triple cells did not significantly alter the expression of the assayed genes (Fig.
5B) even after the addition of retinoic acid, a known ligand of RXRG, to the tissue
culture medium during transfection (Supplemental Figure 3)73. While this result
does not preclude a function for Rxrg in regulating the expression of somatotrope
genes that were not represented in our experimental approach, Rxrg was
excluded from further study in order to focus on transcription factors that impact
the expression of the landmark somatotrope and lactotrope genes.
Both of the lactotrope-enriched factors, Pou4f1 or Nr4a2, were notable for
a significant enhancement in Prl expression when expressed in Pit-1/Triple cells
(Fig. 5C, D). The lack of a significant change in Drd2 expression when these
factors were ectopically expressed suggested that they target expression of the
Prl gene, rather than impacting on multiple genes in the lactotrope transcriptional
program. Taken together, our transcription factor data reveal transcription factor
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actions that either enhance expression of a lineage-defining gene or repress
expression of genes from a competing lineage. These observations further
support a model in which these cells must actively repress the transcriptional
program of the reciprocal lineage to maintain their cell identities and functions.
The function of the transcription factor NR4A2 was further explored by a
combination of ChIP studies and cell transfection assays. NR4A2 ChIP analysis
revealed direct binding to the Prl promoter in Pit-1/Triple cells (Fig. 6B). A
parallel ChIP assay conducted using a primary cell pool enriched for lactotropes
(Fig. 6E) confirmed that this same binding to the Prl promoter occurs in vivo. This
suggests a mechanistic basis for NR4A2 activation of Prl gene expression via a
direct interaction with the Prl promoter, and the concordance of the NR4A2 ChIP
assays in both primary lactotropes and the Pit-1/Triple cell line supports the
validity of using the Pit-1/Triple cell line as an experimental model. qRT-PCR
assays performed on Pit-1/0 cells expressing Pou1f1, Nr4a2, or both factors
together provided further insight into the mechanism of action for Nr4a2 (Fig.
6F). Expression of Pou1f1 alone activated Prl while the expression of Nr4a2
alone had no effect. However, co-expression of Nr4a2 with Pou1f1 resulted in a
significant enhancement of Prl expression over that seen with Pou1f1 alone.
These data suggest that NR4A2 is not sufficient to activate Prl expression on its
own, but that it acts synergistically when POU1F1 is present at the Prl promoter
to enhance Prl expression.
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The positioning of an NR4A2 binding site in the Prl promoter adjacent to a
functionally-defined POU1F1 binding site suggested that its function(s) may
involve enhancement of POU1F1 and occupancy. However, a POU1F1 ChIP
analysis failed to reveal a significant impact of NR4A2 on POU1F1 occupancy at
the Prl promoter (Fig. 7). Additionally, a ChIP analysis of the Gh and Prl
promoters in Pit-1/0 cells transfected with Pou1f1, Nr4a2, or both factors
revealed that POU1F1 establishes H3K27 acetylation and H3K4 tri-methylation
while NR4A2 has no apparent effect on its own, nor does it enhance the
modifications seen with Pou1f1 alone (Fig. 8). Based on these observations we
conclude that NR4A2 enhancement of Prl expression relates to a synergistic
interaction between the two bound factors at the Prl promoter rather than
reflecting enhancements of POU1F1 occupancy or a role in promoting histone
H3K27 acetylation or H3K4 tri-methylation at the target promoter. Reports from
other systems indicate that the family of nuclear orphan receptors to which Nr4a2
belongs is able to heterodimerize with a wide range of transcription factors and
drive transcription84-86, suggesting that NR4A2 might heterodimerize with
POU1F1 or with other, currently unknown, transcription factors at the Prl
promoter to exert its actions on productive transcription.
We next sought to elucidate the mechanism by which the NR4A2 protein
exerts this enhancer effect. Knowing that POU1F1 binds the Prl promoter
independent of NR4A2 occupancy (Fig. 7), we next performed a reciprocal
experiment, performing NR4A2 ChIP using chromatin isolated from Pit-1/0 cells
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to determine whether NR4A2 occupancy at the Prl promoter requires POU1F1
(Fig. 9). These Pit-1/0 cells do not express Pou1f1 or Nr4a2 on their own. After
transfection with either Nr4a2 alone or Nr4a2 and Pou1f1, this ChIP assay
revealed that NR4A2 requires POU1F1 in order to bind the Prl promoter. This
observation is consistent with previous data demonstrating that the enhancement
of Prl gene expression by Nr4a2 is dependent on Pou1f1 actions (Fig. 6F).
These data lead us to propose a model in which POU1F1 binds the Prl promoter
and activates Prl expression, followed by NR4A2 binding at the Prl promoter
which further enhances Prl expression.
Next, we hypothesized that the enhancing activity of NR4A2 reflects its
ability to enhance the recruitment of Pol II to the Prl promoter in the presence of
POU1F1. To test this hypothesis, we performed ChIP for serine 5 phosphorylated
RNA polymerase II (Pol II) at the Prl promoter as well as regions 500 bp
upstream (“Prl upstream”) and 500 bp downstream within the Prl gene body (“Prl
downstream”) (Fig. 10). The serine 5 phosphorylated form of Pol II is associated
with initiation of transcription and active transcription87,88. Serine 5
phosphorylated Pol II occupancy was detected in equal levels at the Prl promoter
in cells that express Pou1f1 alone and in cells that express both Pou1f1 and
Nr4a2, suggesting that Pou1f1 expression is sufficient to recruit Pol II and
assemble a pre-initiation complex (PIC) at the Prl promoter. The Pol II ChIP
studies revealed that Pol II occupancy downstream in the Prl gene body was
markedly enhanced by co-expression of Nr4a2 with Pou1f1. Pol II occupancy at
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the region approximately 500 bp upstream of the Prl promoter is also enhanced
by expression of Pou1f1 and further enhanced by the co-expression of Pou1f1
and Nr4a2. This increase in Pol II occupancy at regions both upstream and
downstream of the Prl promoter may be indicative of bidirectional transcription,
which is a previously described phenomenon at many active promoters89-91. As
was expected, given the lack of NR4A2 in somatotropes and the lack of binding
sites at the Gh promoter, the expression of Nr4a2 in the Pit-1/0 cell line failed to
impact on Pol II occupancy at the promoter or within the body of the Gh gene
(see also Supplemental Figure 6). These data suggest that NR4A2 enhances
the release of Pol II from the Prl promoter and into the Prl gene body for active
transcription.
The basis for the NR4A2-enhanced release of Pol II from the Prl promoter
was further investigated by asking if it reflected an enhanced recruitment of
known release co-factors. While we observed no evidence that NR4A2 enhances
recruitment of the prominent Pol II release factor, P-TEFb (Fig. 11), there are
other mechanisms by which NR4A2 may trigger the release of Pol II such as by
recruiting a different release factor, ejecting a negative release factor, or by
stabilizing the Pol II transcriptional machinery at the Prl promoter. These data
lead us to hypothesize a model in which POU1F1 binds at the Prl promoter and
activates Prl expression. This POU1F1 occupancy is followed by NR4A2 binding
in a POU1F1-dependent manner at the Prl promoter and further increasing the
rate of transcription of Prl by triggering the release of Pol II from the Prl promoter
58

(outlined in Fig. 12). The identity of factor(s) involved in the NR4A2 enhancement
of Pol II release can now be directly addressed as summarized in Chapter V.
The observation of a novel, cell-type enriched transcription factor binding
to the promoter of the Prl gene and acting in conjunction with POU1F1 offers a
potential explanation to the dilemma of Pou1f1 being expressed in both
somatotropes and lactotropes, yet selectively driving the production of one
hormone protein per cell type. While POU1F1 binding at the Gh and Prl
promoters may be ubiquitous in somatotropes and lactotropes, and prime the
respective promoters via targeted histone acetylation, the presence or absence
of additional, lineage-enriched factors such as NR4A2 may be the crucial
determinant of which hormone gene is activated by POU1F1 in a cell. It is also
noteworthy that some factors, such as POU4F1, have effects on the expression
of lineage markers such as Prl, yet are not observed to directly bind the
promoters of either hormone gene (Fig. 6D). These data suggest that POU4F1
acts on other, currently unidentified, regulatory elements to alter the expression
of genes critical to cell identity such as Prl.
In conclusion, these analyses support a model in which cell type-enriched
transcription factors are likely induced during the transition from precursor cells
into a somatotrope or lactotrope. These factors then enhance the expression of
genes crucial to cell identity or suppress the genes that drive the reciprocal
lineage. These factors continue to be expressed in adult pituitary cells, and are
likely needed for the maintenance of cell fate. Mechanistically, these transcription
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factors can act directly at the promoters of their target genes, or indirectly via
additional mediators. The newly identified transcription factors presented here
are likely to represent only a subset of the factors that play important roles in the
maintenance of somatotrope and lactotrope cell identities. The identification of
additional lineage defining determinants is now possible through the analysis of
the transcriptomic profiles of both cell types.
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Figures and legends

Figure 5. Impact of four validated lineage-enriched transcription factors on
expression of somatotrope and lactotrope marker genes in Pit-1/Triple
cells. Pit-1/Triple cells28 were transfected with expression constructs encoding
each noted transcription factor linked by an IRES to a GFP reporter ORF (See
Methods). Transfected cells were isolated by GFP FACS and their RNA content
was assayed for specific marker gene expression by qRT-PCR. A. Nupr1. B.
Rxrg. C. Nr4a2. D. Pou4f1. In all assays, expression of the recombinant
transcription factor was confirmed by targeted qRT-PCR (data not shown). Gene
expression was normalized to an internal Gapdh control and the fold change over
empty vector controls was calculated using the ΔΔCt method (see Methods).
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Gapdh expression levels were stable across all assayed conditions, with no
significant changes in Gapdh expression in any of the transfected samples. Error
bars indicate one standard deviation. Significance calculated by T-test, *
indicates a p-value of <0.05. n = 5 for all experiments.
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Figure 6. The lactotrope-enriched transcription factor, NR4A2, acts in
conjunction with POU1F1 at the Prl promoter to enhance Prl expression. A.
Schematic of the mPrl gene promoter indicating the relative positions of known
POU1F1 binding sites (blue ovals,21) as well as predicted binding sites for
NR4A2 (red ovals) (identified by JASPAR), along with primer positions used for
amplification in ChIP assays (red arrows). B. NR4A2 ChIP. Pit-1/Triple cells were
transfected with an expression vector encoding NR4A2 and chromatin isolated
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from GFP+ cells (as in Fig. 5) was assayed by NR4A2 ChIP. Levels of
transcription factor occupancy at specific sites within the Prl promoter were
quantified by qRT-PCR of immunoprecipitated samples. Parallel controls
included quantitation of occupancy at the Gh promoter and assessment of
binding in regions 500 bp upstream and downstream of Prl promoter. The MyoD
promoter served as a negative control in all studies. C. Schematic of the mPrl
gene promoter indicating the relative positioning of known POU1F1 binding sites
(blue ovals) as well as predicted binding sites for POU4F1 (green ovals)
(identified by JASPAR). D. POU4F1 ChIP. Pit-1/Triple cells were transfected with
an expression vector encoding POU4F1 and chromatin isolated from GFP+ cells
(as in B.) was assayed by ChIP. The Pou4f1 enhancer, which contains an
autoregulatory POU4F1 binding site, was assayed in this study as a positive
control for the POU4F1 ChIP76. E. NR4A2 ChIP on FACS sorted mouse
lactotropes revealed a similar binding profile as that observed in Pit-1/Triple cells,
confirming the validity of the cell line model. F. NR4A2 enhances Pou1f1dependent activation of the Prl gene in Pit-1/0 cells. Pit-1/0 cells were transfected
with expression vectors encoding Pou1f1, Nr4a2, or both linked by IRES to GFP,
and GFP+ cells were collected by FACS. qRT-PCR analysis was performed to
measure changes in mRNA expression of somatotrope and lactotrope marker
genes. *: p-value <0.05. **: p-value <0.01. ***: p-value <0.001. n = 3 for all
experiments.
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Figure 7. NR4A2 has no significant impact on POU1F1 occupancy at the Prl
promoter. POU1F1 chromatin immunoprecipitations were carried out on Pit1/Triple cells +/- Nr4a2. Pit-1/Triple cells, which do not express Nr4a2 on their
own, were transfected with an Nr4a2 expression vector (the same Nr4a2-IRESGFP plasmid used in assays presented in Fig. 5C), and control cells were
transfected with the empty IRES-GFP vector. GFP positive cells were sorted by
FACS, chromatin was isolated, and ChIP was performed using an antibody that
recognizes POU1F1. Following immunoprecipitation, qRT-PCR was used to
measure the relative levels of POU1F1 binding in Pit-1/Triple cells that had been
transfected with Nr4a2 plasmid (+Nr4a2), and those transfected with empty
vector. Immunoprecipitations using IgG served as a negative control. * indicates
p-value <0.05. N = 3 biological replicates.
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Figure 8. Expression of Nr4a2 does not impact levels of histone 3 lysine 27
acetylation or histone 3 lysine 4 tri-methylation. Pit-1/0 cells, which express
neither Nr4a2 nor appreciable levels of Pou1f1, were transfected with Nr4a2IRES-GFP, Pou1f1-IRES-GFP, or a 1:1 mixture of both expression vectors, and
control cells were transfected with an empty IRES-GFP vector. Cells transfected
with the 1:1 mixture of the Pou1f1 and Nr4a2 expression vectors express lower
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levels of each protein due to the concentration of each expression vector being
halved during transfection in order to keep the total amount of DNA constant in
each transfection. GFP positive cells were isolated by FACS and chromatin was
isolated. ChIP was performed using an antibody that recognizes histone 3 lysine
27 acetylation (H3K27ac) (A.), or an antibody that recognizes histone 3 lysine 4
tri-methylation (H3K4me3) (B.). Following chromatin immunoprecipitation, qRTPCR was performed to assay the levels of each marker at the Gh promoter, the
Prl promoter, and the MyoD promoter as a negative control. IgG controls (data
not shown) were also included in this assay for all samples. In all cases, ChIP
performed with IgG yielded <1% of input. * indicates a p-value <0.05. N = 3
biological replicates.
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Figure 9. NR4A2 binding at the Prl promoter is POU1F1 dependent. Pit-1/0
cells were transfected with plasmids expressing either Nr4a2 or Pou1f1 linked by
IRES to a GFP reporter as in Figure 6. GFP positive transfected cells were
collected and chromatin was isolated before performing ChIP for the NR4A2
protein. NR4A2 occupancy was assayed at the promoters of Gh, Prl, Pou1f1, and
Myod as a control. * indicates p-value <0.05 as determined by Student’s T-test. N
= 3 biological replicates.
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Figure 10. NR4A2 enhances the release of Pol II from the Prl promoter into
the gene body. Pit-1/0 cells were transfected with either Pou1f1 alone, or with a
combination of Pou1f1 and Nr4a2, with untransfected cells serving as a negative
control. ChIP was performed for serine 5 phosphorylated Poll II and binding was
quantified by qPCR. The Gh, Pou1f1, and Prl promoters were assayed along with
upstream and downstream controls for specificity. Here, “upstream” refers to
regions 500 bp upstream of the canonical promoters and “downstream” refers to
500 bp downstream of the promoters, inside the gene body. * indicates p-value
<0.05, ** indicates p-value <0.01 as determined by Student’s T-test. N = 3
biological replicates.

69

Figure 11. NR4A2 fails to enhance Cdk9 recruitment at the Gh and Prl
promoters. Pit-1/0 cells were transfected with plasmids expressing Pou1f1 alone
or co-expressed with expression constructs for both Pou1f1 and Nr4a2 and
chromatin immunoprecipitation was performed using an antibody against the
Cdk9 subunit of the release factor P-TEFb. RT-PCR was performed to assay
Cdk9 occupancy at the Gh and Prl promoters, with the Pou1f1 and Myod
promoters serving as positive and negative controls, respectively. N = 3
biological replicates.
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Figure 12. Model of the role of NR4A2 in enhancing the expression of Prl.
POU1F1 binds the Prl promoter independently of NR4A2 (1) and triggers histone
acetylation and tri-methylation throughout the Prl promoter by recruiting histone
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acetyltransferases and methyltransferases, respectively (2). POU1F1 is able to
recruit Pol II to the Prl promoter, which activates transcription and leads to some
measure of Prl expression (3). NR4A2 binds the Prl promoter only in the
presence of POU1F1, potentially recruiting a release factor to the complex (4),
and further enhances the rate of Prl transcription by triggering an increase in the
rate of Pol II release from the Prl promoter (5).
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Supplemental Data

Supplemental Figure 3. RXRG has no impact on the expression of
signature somatotrope or lactotrope genes in the presence of retinoic acid.
Pit-1/Triple cells were transfected with an Rxrg expression vector as in Fig. 5 and
grown in culture medium supplemented with 10 mM retinoic acid (RA). Cells
transfected with an empty vector control were grown in both with and without RA
added to the culture medium. Two days after transfection, RNA was collected,
cDNA generated, and qRT-PCR for each of the indicated mRNAs was performed
as in Fig. 5. Egr1 was included as a positive control for RA effect based on a
previous report that it is transcriptionally activated by retinoic acid74 and is
expressed in Pit-1/Triple cells (data not shown). All data was normalized to the
Gapdh mRNA signal. Rxrg expression from the Rxrg expression vector was
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confirmed in transfected cells by PCR (data not shown). N=3, * = p-value <0.05
as determined by Student’s T-test.

74

Supplemental Figure 4. Western blot validation of POU1F1 antibody
specificity. POU1F1 antibody was used to perform a western blot on lysate from
the murine Pit-1/Triple cells (lane 1), producing a band of 33 kDa corresponding
to endogenous POU1F1. Lysate from human 293T cells (lane 2) produce no
bands (293T cells do not express POU1F1). 293T cells transfected with a biotin
ligase receptor peptide (2.5 kDa) epitope-tagged version of POU1F1 (lane 3)
produces a band with a corresponding shift in size in accordance with the
additional epitope added to POU1F1 (33 kDa to 36 kDa).
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Supplemental Figure 5. NUPR1 is present in a majority of
somatolactotropes. A representative immunofluorescence microscopy image of
wild-type female mouse pituitary cells that were disaggregated and immunostained for NUPR1, GH, and PRL. Multiple somatotropes (white arrows) can be
seen which stain strongly for NUPR1, along with a single somatolactotrope
(GH+/PRL+) (red arrow) that also is positive for NUPR1. Two GH-/PRL- cells are
also visible which stain much more weakly for NUPR1. In this experiment, a total
of 50 somatolactotropes (GH+/PRL+) were identified (out of approximately 2000
pituitary cells imaged) and assayed for NUPR1 expression. Of these 50
somatolactotropes, 27 (54%) were positive for NUPR1.
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Supplemental Figure 6. Expression of Pou1f1 in Pit-1/0 cells drives
productive transcription of Prl as compared with the production of short,
abortive transcripts from the Gh promoter. A. Schematic of PCR amplification
strategy to detect short, abortive transcripts. The intron/exon structure of the Gh
and Prl genes is remarkably similar, and so this five exon schematic represents
both the Gh and Prl genes as the primer design (orange arrows) approach was
similar for both genes. A shared forward primer was placed at the transcription
start site (TSS) and two reverse primers, one 50 bp downstream of the TSS and
one 100 bp downstream of the TSS were combined with the forward primer to
analyze abortive transcripts. Exon-spanning primers were designed further into
the gene body (“gene body” primers) to assay productive, elongated transcripts.
B. Quantitative RT-PCR was performed using these primer sets in Pit-1/0 cells
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that had been transfected with plasmids expressing Pou1f1 +/- Nr4a2. RNA was
isolated and treated with DNase to eliminate genomic DNA contamination. N = 3
biological replicates. * indicates a p-value <0.05 while ** indicates a p-value <
0.01.
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CHAPTER IV: IN VIVO FUNCTIONAL
CHARACTERIZATION OF NEWLY IDENTIFIED
TRANSCRIPTION FACTORS BY CONDITIONAL GENE
INACTIVATION IN TRANSGENIC MOUSE MODELS
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Introduction
Having identified a set of transcription factors that are enriched in
somatotropes and lactotropes and appear to have functional impacts on the
expression of crucial somatotrope and lactotrope genes, a key challenge was to
validate these function(s) in the in vivo. Nr4a2, Nupr1, and Pou4f1 were selected
for further study based on their functional impacts on landmark somatotrope and
lactotrope genes in the context of our cell line model system (Chapter III). These
transcription factors may be important regulators of the maintenance of
somatotrope/lactotrope cell fate in terminally differentiated cells, by enhancing
landmark genes of a cell lineage, or in reciprocally repressing the landmark
genes of a divergent lineage. It is crucial to understand the effect these
transcription factors have on the cell identity of somatotropes and lactotropes in
the context of primary pituitary cells in order to gain a more complete
understanding of their mechanisms of action and contribution(s) to the cellular
composition and hormonal functions of the intact pituitary.
Given the effects of the two lactotrope transcription factors Nr4a2 and
Pou4f1 on Prl expression in our cell-based assays, we hypothesized that their
ablation in the lactotropes of mice might result in a decrease in Prl expression
and/or a decrease in lactotrope representation in the pituitary. We anticipated
that impacts of the deletions of these factors might be detected at the cellular
level by decreases in the number or intensity of PRL+ cells, by decreases in Prl
mRNA in total pituitary RNA, and/or lactation or maternal activity phenotypes.
Our cell-based data would predict that deletion of either of these transcription
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factors would only have a partial impact on Prl expression because Pou1f1 is
sufficient in the absence of either factor to drive Prl expression to appreciable
levels (Fig. 6F)92, an observation consistent with studies that have identified
Pou1f1 as a major activator of Prl expression8,9,21. Thus, mice lacking either
Nr4a2 or Pou4f1 in lactotrope cells are predicted to maintain an appreciable level
of Prl expression, albeit at levels lower than those observed in wild-type mice.
A third transcription factor of interest based on our prior cell-based studies
is Nupr1. This factor is enriched in somatotropes and appears to be involved in
the repression of two lactotrope-specific proteins; Prl and Drd2. These data
suggest that lactotrope-defining genes are under active repression in
somatotropes and that the deletion of Nupr1 in primary mouse somatotropes
might therefore result in a de-repression of Prl in the somatotropes. Thus, we
would predict that mice with a selective ablation of Nupr1 in somatotropes might
exhibit conversion of a subset of somatotropes to a dual positive state
(GH+/PRL+).
We describe in this Chapter a series of studies that were designed to
validate the roles of the three identified transcription factors in primary
somatotropes and lactotropes. This was accomplished by obtaining and/or
generating lines in which the genes encoding each of the three transcription
factors could be inactivated in a cell-type specific manner. To achieve this goal,
we crossed mouse lines that selectively express Cre recombinase in either
somatotropes or in lactotropes with lines in which each of the three target loci
were flanked by LoxP elements (“floxed” mouse lines). Compound transgenic
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progeny (Cre x Flox/Flox), were studied to probe the function of each
transcription factor in the respective cell lineage. Here, we present data from
these cell type specific knockout mouse lines to demonstrate that two of the
newly identified somatotrope/lactotrope enriched transcription factors, Nupr1 and
Nr4a2, have respective repressing and enhancing actions on Prl expression in
somatotropes and lactotropes within the adult murine pituitary. These
observations in an in vivo setting are consistent with the activities observed in our
cell culture-based studies (Chapter III) and provide an expanded understanding
of somatotrope and lactotrope regulation.
Results
Generation and validation of mouse lines that support conditional
inactivation of targeted transcription factors in the somatotrope or
lactotrope lineages
To generate inactivating mutations of selected transcription factors
specifically in somatotropes or lactotropes, we needed mouse lines that express
Cre recombinase under the control of either the Gh or Prl regulatory elements.
An existing Gh-Cre mouse line that has been validated for expression of Cre in
somatotropes16 was provided by the lab of Dr. Sally Camper. A corresponding
Prl-Cre mouse line was not available, so we generated this line by inserting the
Cre ORF into the second exon of the Prl gene within the context of a 200 kb
bacterial artificial chromosome (BAC) containing the mouse Prl locus. The BAC
clone used for this insertion was selected based on its extensive (>50 kb)
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sequences both 5’ and 3’ of the Prl gene. In the absence of evidence that the
mPrl gene is under remote regulatory control93, the presence of these extensive
flanking sequence was assumed to be sufficient to drive lactotrope-specific
expression (Fig. 13A). The recombinant BAC was generated by standard BAC
recombineering (see Methods) and was microinjected into B6SJLF1/J mouse
embryos by the Penn Transgenic Mouse facility94. After establishing a line of
transgenic mice carrying this Prl-Cre transgene, the mice were crossed with mice
(provided by Dr. Douglas Epstein) carrying a ZsGreen reporter gene with an
upstream lox-stop-lox to identify sites of Cre recombinase expression95.
In order to validate the accuracy of Cre expression from the Prl-Cre
transgene, we collected pituitaries from mice carrying both the Prl-Cre and
ZsGreen transgenes (Prl-Cre/ZsGreen). These pituitaries were disaggregated,
and immunostained for GH, PRL, and ZsGreen using an anti-GFP antibody (Fig.
13B). 91% of PRL positive lactotropes were also positive for the ZsGreen
reporter protein, while only 1.1% of all GH positive somatotropes expressed
ZsGreen (Fig. 13C). These data indicated robust lactotrope specificity for the
expression of Cre recombinase. This lactotrope-specific Cre line was used along
with the previously established somatotrope-specific Cre line for the subsequent
conditional knockout studies16. The specificity of the Gh-Cre mouse line,
previously described16, was similarly assayed and validated (Supplemental
Figure 7).
Having established mouse lines expressing somatotrope/lactotrope
specific Cre recombinase, we next focused on obtaining mouse lines carrying
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floxed alleles of each of the three transcription factors of interest: Nupr1, Pou4f1,
and Nr4a2. Existing lines carrying floxed alleles of Pou4f1 and Nr4a2 were
obtained from cooperating labs (the labs of Dr. Tudor Badea96 and Dr. Thomas
Perlmann97, respectively). We generated the remaining mouse line carrying a
floxed Nupr1 allele in conjunction with the Penn CRISPR/Cas9 Mouse Targeting
Core. LoxP elements were inserted flanking exon 2 of endogenous Nupr1 locus.
The positioning of these LoxP elements was chosen based on previous reports
that germline deletion of exon 2 is sufficient to abolish NUPR1 activity in the
mouse98. Together with the somatotrope and lactotrope specific Cre lines, the
three floxed mouse lines allowed us to selectively delete each transcription factor
specifically in the somatotrope or lactotrope lineages.
Deletion of Nr4a2 in lactotropes causes a decrease in prolactin expression
in mouse pituitary
In our preceding studies we demonstrated in a cell line model and in
primary pituitary cells that the orphan nuclear receptor NR4A2 binds within the
Prl promoter at a site that is adjacent a known POU1F1 binding site. We further
demonstrated by transfection studies in the Pit-1/0 cell line that forced expression
of Nr4a2 enhanced Prl expression in a POU1F1 dependent manner (Fig. 6F)92.
To validate and extend these findings in vivo, we generated Nr4a2flox/flox; Prl-Cre
mice and performed immunofluorescence microscopy on disaggregated cells
from their pituitaries. Control mice that were homozygous for the floxed allele of
Nr4a2 but negative for Cre recombinase (Nr4a2flox/flox) expressed NR4A2 in
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nearly all lactotropes (90%, N = 371 PRL+ cells) (Fig. 14A). This percentage of
lactotropes expressing the NR4A2 protein is consistent with that seen in wild type
mice (Fig. 4D), confirming that the inserted loxP sites do not affect expression of
the Nr4a2 gene. In clear contrast, we observed a dramatic decrease in the
number of cells that expressed NR4A2 in Nr4a2flox/flox; Prl-Cre mice, where
NR4A2 protein was expressed at detectable levels in only 31% of the PRL+ cells
(N = 393 PRL+ cells.). These data lead us to conclude that Nr4a2flox/flox; Prl-Cre
mice exhibit greatly reduced NR4A2 expression in lactotrope cells, confirming
successful ablation of Nr4a2 in the majority of lactotrope cells.
Next, an immunofluorescence study was performed to determine the
impact of Nr4a2 ablation on PRL expression in mouse lactotropes. De-identified
slides produced from pituitary cells isolated from littermates with Nr4a2flox/flox or
Nr4a2flox/flox; Prl-Cre genotypes were stained for GH and PRL. We observed that
the pituitaries isolated from Nr4a2flox/flox; Prl-Cre mice had approximately half as
many PRL+ cells as their Nr4a2flox/flox littermates (Fig. 14B) while the numbers of
GH+ cells and dual GH+/PRL+ cells were not significantly different between these
two groups. This reduction in PRL expression was paralleled by RT-PCR assays
of mRNA levels, demonstrating an approximately 40% decrease in Prl mRNA in
the pituitaries of Nr4a2flox/flox; Prl-Cre mice as compared to littermate controls
(Fig. 14C). These data suggest that Nr4a2 expression is required for robust Prl
expression in mice. The marked depletion of NR4A2 in 70% of lactotrope cells
(Fig. 14A) corresponded to a loss of approximately 50% of PRL positive cells
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(Fig. 14C), supporting a correlation between the amount NR4A2 ablation and the
loss of PRL expression.
Deletion of Nr4a2 in lactotropes leads to the presence of “silent”
lactotropes in the anterior pituitary.
The approximately 50% decrease in PRL positive cells observed in the
pituitaries of mice lacking Nr4a2 in lactotropes may be the result of a loss of
lactotrope cells in the absence of Nr4a2, leading to a decrease in the number of
lactotropes in the pituitaries of Nr4a2flox/flox; Prl-Cre mice. However, an alternate
explanation is that Nr4a2flox/flox; Prl-Cre mice have the same number of
lactotropes as their Nr4a2flox/flox littermates, but only ~50% of these “lactotropes”
actively express PRL. In this second model, the deletion of Nr4a2 in lactotropes
leads to the presence of “PRL-silent” lactotropes, i.e., lactotropes that are
negative for PRL staining. In an effort to distinguish between these two models,
we stained the pituitaries of Nr4a2flox/flox; Prl-Cre mice and Nr4a2flox/flox littermates
for PRL and POU1F1. POU1F1 is expressed in the three Pou1f1 lineages: the
somatotropes, the lactotropes, and the TSH-producing thyrotropes. Since
thyrotropes constitute <5% of anterior pituitary cells, while somatotropes and
lactotropes can range from 30-50% of all anterior pituitary cells1,2, nearly all
POU1F1 positive cells in the anterior pituitary are either GH-positive
somatotropes or PRL-positive lactotropes. By staining for these two proteins, we
would predict that the presence of “PRL-silent” lactotropes could be detected by
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observing an increase in the amount of POU1F1+/PRL- cells in Nr4a2flox/flox; PrlCre as compared to Nr4a2flox/flox littermates.
Consistent with this prediction, immunofluorescence microscopy revealed
an increase in the amount of POU1F1+ cells that do not express PRL in
Nr4a2flox/flox; Prl-Cre mice, as indicated by a significantly higher ratio of
POU1F1+/PRL- to POU1F1+/PRL+ cells in their pituitaries (ratio of 4.72) as
compared to Nr4a2flox/flox littermate controls (ratio of 1.64) (Fig. 15 A and B). This
observation suggests a reduction of Prl-expressing cells within the pituitaries of
Nr4a2flox/flox; Prl-Cre mice, but not a loss in the total number of POU1F1+ pituitary
cells. Notably, a subset of cells that co-express both POU1F1 and PRL (Fig.
15B, white arrow) can be detected in Nr4a2flox/flox; Prl-Cre mice, suggesting that
while the number of PRL+ lactotropes has decreased, there is not a complete
loss of this cell population. This increase in POU1F1+/PRL- cells (Fig. 15C) in the
pituitaries of mice that have ablated expression of Nr4a2 in their lactotrope cells
suggests that loss of Nr4a2 does not cause complete loss of the cell population,
but rather causes a loss of Prl expression in adult lactotropes, rendering them
PRL-silent lactotropes (POU1F1+/PRL- cells).
Deletion of the lactotrope-enriched transcription factor Pou4f1 in adult
mouse lactotropes fails to alter Prl expression
Pou4f1 was identified as a second lactotrope-enriched transcription factor
that had a positive impact on Prl expression when tested in our Pit-1/Triple cell
line model system (Chapter III)92. These results predict that inactivation of
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Pou4f1 in the lactotropes of the mouse pituitary would have a negative impact on
the expression of Prl and/or the number of PRL positive lactotropes. Such
findings would parallel those observed after conditional deletion of Nr4a2 in
lactotropes. A comparison of pituitaries from Pou4f1flox/flox; Prl-Cre mice and their
control Pou4f1flox/flox littermates by targeted RT-PCR confirmed a significant
reduction in the level of Pou4f1 expression in the pituitaries of Pou4f1flox/flox; PrlCre mice (Pou4f1 mRNA levels at 30% those observed in Pou4f1flox/flox control
mice). However, the study failed to reveal a corresponding decrease in Prl mRNA
expression or an impact on any of the assayed landmark somatotrope or
lactotrope specific genes. Furthermore, a set of parallel IF studies failed to reveal
any significant differences in the representations of somatotropes and lactotropes
within the pituitary cell populations (Fig. 16). These in vivo data suggest that
Pou4f1 does not play a significant role maintaining the expression of Prl in the
lactotropes or in maintaining the cellular composition of the pituitary when studied
in adult mice. What remains a possibility is that the impact of Pou4f1 on Prl
expression in the Pit-1/Triple cell model reflects a role in lactotrope development
at an earlier developmental stage of the pituitary rather than in terminally
differentiated lactotropes as previously hypothesized. Such a model can be
tested in future studies (see Chapter V).
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Deletion of the somatotrope-enriched transcription factor Nupr1 in mouse
somatotropes causes ectopic expression of PRL in somatotropes
While the lactotrope-enriched transcription factors Nr4a2 and Pou4f1 were
selected for study due to their observed positive effects in enhancing Prl
expression, the somatotrope-enriched transcription factor Nupr1 was chosen for
further study based on our data pointing to a role in repressing two landmark
lactotrope markers, Prl and Drd2, in the Pit-1/Triple cell line92 (Fig. 5A). Such a
role would predict that the ablation of this locus in the somatotrope lineage might
result in a de-repression of Prl and Drd2 in the somatotropes, with an increase in
the number of dual positive (GH+/Prl+) cells in the pituitary. To test this model that
Prl gene expression is actively repressed in somatotropes by Nupr1, we first
assayed the impact of a conditional inactivation of Nupr1 in somatotropes of adult
mice carrying the Nupr1 floxed allele. Pituitaries of Nupr1flox/flox; Gh-Cre mice and
their Nupr1flox/flox littermates were assayed for Prl mRNA expression by RT-PCR
(Fig. 17A). We observed that expression of Nupr1 was significantly reduced in
the pituitaries of Nupr1flox/flox; Gh-Cre mice as compared to their Nupr1flox/flox
littermates, thus confirming the conditional inactivation of the Nupr1 allele. This
ablation of Nupr1 resulted in a significant (2.7-fold) increase in Prl levels in the
pituitary. While this increase in Prl mRNA was consistent with our previous
observations (Fig. 5A), the parallel impact on the lactotrope-specific gene Drd2
was not observed. These data obtained from analysis of the whole pituitary are
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consistent with a repressive function for Nupr1 on the expression of Prl in the
somatotrope cells.
To further investigate the impact of Nupr1 in the adult pituitary, we
assayed the pituitaries of Nupr1flox/flox; Gh-Cre and Nupr1flox/flox mice by
immunofluorescence microscopy (Fig. 17B) for alterations in the representations
of the Pou1f1 dependent lineages. Dispersed pituitary cells were stained with
antibodies against GH and PRL and cells were counted in a blinded manner as
previously described. These IF studies revealed a significant decrease in the
number of somatotropes (GH+/PRL- cells) in the pituitaries of Nupr1flox/flox; Gh-Cre
mice, from 22% of all pituitary cells in Nupr1flox/flox control mice to 14% of all
pituitary cells in Nupr1flox/flox; Gh-Cre mice (Fig. 17C). Importantly, the decrease
in the number of somatotropes was matched by a reciprocal increase in the
number of dual positive GH+/PRL+ cells from 2% in Nupr1flox/flox mice to 9% in
Nupr1flox/flox; Gh-Cre mice (Fig. 17D). GH+/PRL+ cells, typically classified as
“somatolactotrope” cells, are rare within wild-type adult mouse pituitaries,
constituting approximately 1-2% of total cells1,12,13. The increase in the number of
such cells in Nupr1flox/flox; Gh-Cre to 9% suggests that inactivation of the Nupr1
gene in somatotropes resulted in de-repression of the Prl gene. This derepression led to the appearance of somatotropes co-expressing both GH and
PRL, a phenotype that is typically categorized as a “somatolactotrope” cell. Thus,
our cell culture studies and the conditional gene inactivation studies are
concordant in assigning a repressive function to Nupr1 at the Prl locus in
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somatotropes. These findings lead us to conclude that landmark gene(s) of the
lactotrope cell identity (i.e., Prl) must be actively repressed in somatotropes in
order to maintain somatotrope cell identity in the adult pituitary (summarized in
Fig. 18).
Discussion
Despite recent advances in understanding the regulation of the
somatotrope and lactotrope lineages in the anterior pituitary92, many questions
remain. The three transcription factors that we focus on in these studies, Nr4a2,
Pou4f1, and Nupr1 were determined, on the basis of cell culture assays, to be
regulators of Prl. Two of these factors enhance Prl expression in the context of a
murine pituitary cell line model (Nr4a2 and Pou4f1), while the third factor (Nupr1)
suppresses expression of both Prl and Drd2. Thus all three of these transcription
factors are observed to act on Prl gene expression, but are likely to be acting
through a variety of mechanisms. These data suggest a previously unrecognized
complexity in the regulation of hormone genes in the somatotrope and lactotrope
lineages in the mouse pituitary. Knowledge of the mechanisms of action for
transcription factors involved in enhancing or repressing expression of hormones
may provide future studies with potential targets for therapeutics in treating
disorders of the somatotrope/lactotrope lineages.
We began these studies by developing transgenic mouse lines that would
allow us to probe the effect(s) of each transcription factor in the context of
primary somatotropes and lactotropes in the adult pituitary. While some of the
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required mouse lines were already available and were generously provided by
their respective labs (Gh-Cre16,99, Nr4a2flox 97, and Pou4f1flox 96), lines for a
lactotrope-specific Cre and a Nupr1flox allele had to be generated de novo. A PrlCre line was established using BAC recombineering techniques (see Methods)
to insert the Cre ORF into the second exon of the Prl gene in the context of a
BAC containing the region of the mouse genome (~200 kb) containing the Prl
locus. Mice carrying this transgene were validated for lactotrope specific Cre
expression (Fig. 13), establishing a lactotrope-specific Cre mouse line to
complement the existing Gh-Cre mouse line. A Nupr1flox line was generated by
the CRISPR/Cas9 Mouse Targeting Facility (see Methods) and validated for
insertion of the LoxP sites via PCR and sequencing. Together, this set of mouse
lines with floxed alleles and with lineage-specific Cre drivers allowed us to
explore the in vivo functions of the selected transcription factors and to determine
their roles in maintaining the somatotrope and lactotrope lineages in the adult
pituitary.
Ablation of the lactotrope-enriched factor, Nr4a2, reduces Prl expression in
a subset of lactotropes
We focused our initial studies on the transcription factor Nr4a2. This factor
enhances Prl expression in the context of a cell line model system by binding to
the Prl promoter (Fig. 5C)92. The majority of lactotropes (69%, N = 393 PRL+
cells) in Nr4a2flox/flox; Prl-Cre mice did not express substantial amounts of NR4A2
protein as assayed by immunofluorescence microscopy (Fig. 14A). The
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remaining 31% of lactotropes did express NR4A2, indicating that ablation of
NR4A2 in these mice is not total, but is substantially reduced in comparison to
Nr4a2flox/flox littermate controls, where 90% (N = 371 PRL+ cells) express NR4A2.
Interestingly, we observe a subset of lactotropes in Nr4a2flox/flox; Prl-Cre mouse
pituitary that is depleted of NR4A2 but still produces PRL (Fig. 14A, right panel).
The reduction in the number of lactotropes was quantified via blinded
immunofluorescence microscopy assays to ensure that there were no biases in
the cell counting (Fig. 14B). Notably, approximately half of the lactotrope
population persists in the pituitaries of Nr4a2flox/flox; Prl-Cre mice, suggesting that
although Nr4a2 is an important regulator of the lactotrope lineage, it is not the
sole determinant of this cell type.
It is noteworthy that a subset of lactotropes show a complete loss of PRL
protein expression as assayed by immunofluorescence microscopy, rather than a
partial loss of PRL expression as initially hypothesized. While further study is
necessary to determine the cause of the complete loss of PRL expression from
some lactotropes, one interesting possibility is that there are multiple sub-types
of lactotrope cells. It is possible that there exists a lactotrope sub-type that
cannot express Prl in the absence of Nr4a2 while there exists one or more subtype(s) that can continue to express Prl in the presence of Pou1f1 alone. The
existence of such lactotrope sub-types would be consistent with single-cell RNA
sequencing analysis that shows evidence of multiple sub-populations of
lactotrope cells within the murine pituitary (Ho et al., In review). Consistent with
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the detection of a 45% loss of cells expressing the PRL protein, Prl mRNA levels
are also reduced by approximately 40% in Nr4a2flox/flox; Prl-Cre mice (Fig. 14C).
Together, these data support the hypothesis that Nr4a2 represents a nonredundant enhancer of Prl gene expression.
To further characterize the loss of PRL expressing lactotropes in
Nr4a2flox/flox; Prl-Cre mice, we performed immunofluorescence microscopy by costaining for POU1F1 and NR4A2. POU1F1 is the primary known activator of both
Gh and Prl expression and is essential to the development of the somatotrope
and lactotrope populations21,39. Based on our previous studies, ablation of Nr4a2
is not expected to impact the expression of Pou1f1 and therefore, even if Prl
expression is lost, Pou1f1 will remain expressed in lactotrope cells and can be
used as a marker. The majority of POU1F1 positive cells in the pituitary are
either somatotropes or lactotropes, with thyrotropes comprising only 5% of the
total cells1. Thus, co-staining for POU1F1 and NR4A2 in the pituitaries of
Nr4a2flox/flox; Prl-Cre mice and Nr4a2flox/flox littermate controls can be used to
detect the presence of “silent” lactotropes: lactotrope cells that express POU1F1
and other lactotrope proteins, but no longer express PRL due to deletion of a
transcription factor such as Nr4a2.
Using this method, ablation of Nr4a2 in lactotropes was observed to cause
a significant shift in the ratio of POU1F1 positive, PRL negative cells to POU1F1
positive, PRL positive lactotropes in comparison to the ratio observed in
littermate controls (Fig. 15). This result suggests that “lactotrope” cells are still
94

present in the pituitaries of Nr4a2flox/flox; Prl-Cre mice, but that they no longer
express prolactin. Further study is ongoing to confirm that these POU1F1+/PRLcells are also negative for GH. These data suggest that ablation of Nr4a2 causes
a loss of prolactin expression in lactotrope cells, rather than an outright loss of
lactotropes, as evidenced by the increase in POU1F1 single positive cells in
Nr4a2flox/flox; Prl-Cre mice. Taken together with previous data, this study indicates
that Nr4a2 likely plays a role in maintaining the expression of Prl in the
lactotropes of adult mice.
The lactotrope-enriched transcription factor, Pou4f1, failed to impact Prl
expression in mice
In addition to our studies on the role of Nr4a2 in lactotrope cells, we also
assayed the effect of Pou4f1 in lactotropes with our hypothesis being that Pou4f1
plays a similar role to Nr4a2 in these cells due to its similar effect on Prl
expression in previous cell line studies (Fig. 5D). However, both
immunofluorescence microscopy (Fig. 16A and B) and RT-PCR (Fig. 16C) failed
to reveal any evidence that Pou4f1flox/flox; Prl-Cre mice have lower levels of Prl
expression or fewer lactotropes than their Pou4f1flox/flox littermates, although a
reduction of Pou4f1 mRNA was confirmed, indicating successful ablation of
Pou4f1. These data contrast with previous data from mouse pituitary cell lines
(Fig. 5D) and may suggest that Pou4f1 does not play a role in the regulation of
Prl expression in the lactotropes of adult mice. Conversely, it is possible that
Pou4f1 plays a role in the regulation of Prl, but there is another gene or genes
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that are functionally redundant with Pou4f1, such that deletion of Pou4f1 alone is
not sufficient to impact Prl expression in mice. Alternatively, Pou4f1 may play a
role in an earlier stage of lactotrope development, prior to Prl expression. Testing
this possibility would require producing mice that carry both the Pou4f1flox/flox
allele as well as a Cre recombinase transgene that is expressed at an earlier
stage of pituitary development than the Prl-Cre used in these studies.
Development of such mice falls outside the scope of the present study, but is an
interesting topic for future studies to assay and is discussed further in Chapter V.
The somatotrope-enriched transcription factor, Nupr1, represses Prl
expression in somatotrope cells
In contrast to lactotrope-enriched transcription factors such as Nr4a2
which enhances Prl expression, we also assayed a somatotrope-enriched
transcription factor, Nupr1, that our cell based assay suggested has a repressing
effect on Prl expression (Fig. 5A). Nupr1flox/flox; Gh-Cre mice have fewer
somatotropes (GH+/PRL-) in their pituitaries than Nupr1flox/flox littermate control
mice, and demonstrate a robust increase in the representation of GH/PRL dual
positive cells (Fig. 17). Conventionally, such dual positive cells are identified as
somatolactotropes and constitute 1-2% of the adult pituitary population1. As
noted earlier (see Chapter I), the origin of the somatolactotrope cells remains
ambiguous, with some reports identifying them as precursors to both the
somatotropes and the lactotropes2 while others hypothesize that they are a
transitional state between somatotropes and lactotropes13. While a conventional
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somatolactotrope and a GH/PRL dual positive cell that arises from de-repression
of Prl expression in Nupr1flox/flox; Gh-Cre mice may appear indistinguishable by
immunofluorescence microscopy with GH/PRL staining, it should be noted that
they are not necessarily identical nor are they necessarily generated by similar
mechanisms. Somatolactotropes may have currently unknown traits or
transcriptomic differences which distinguish them from the somatotropes and
lactotropes beyond simply co-expressing GH and PRL. In contrast, the GH/PRL
dual positive cells observed after deletion of Nupr1 in mouse somatotropes may
simply be somatotropes that are ectopically expressing Prl with no further
changes in cell identity, a distinction that will require a better understanding of the
somatolactotrope cells to resolve.
While this distinction between somatolactotropes and somatotropes that
ectopically express PRL may appear minor, it raises a question that has been
central in the study of anterior pituitary cell types, yet remains incompletely
answered: how does one define a somatotrope or a lactotrope? Conventionally,
cells that express GH alone are defined as somatotropes while cells that express
PRL alone are categorized as lactotropes. This classification paradigm has been
useful in the study of these cells, but it obfuscates the lack of a deep
understanding of somatotrope/lactotrope cell identity. As previously discussed
(Chapter I), there are few genes that can be classified as crucial to the
somatotrope or lactotrope cell identities beyond the hormone genes themselves,
Gh and Prl, and receptors for hypothalamic signals such as Ghrhr and Drd2,
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respectively. Without knowledge of more genes that are essential to the
somatotrope/lactotrope identities, it is a challenge to classify these cells in a truly
meaningful way. Classifying somatotropes/lactotropes purely by their expression
of the GH or PRL proteins may be sufficient when describing the normal, adult
pituitary, but it is less useful for studies in which perturbations of transcription
factors such as Nr4a2 or Nupr1 occur.
Defining a cell type by its expression of a hormone alone may be
problematic. For example, if a lactotrope ceases to express PRL, as seen when
Nr4a2 is deleted (Fig. 13), should it still be classified as a lactotrope? Drd2, while
enriched in lactotropes, is also expressed in other pituitary cells100, and thus
cannot be used to classify lactotropes without other identifying marks to
supplement it. The only method of addressing this problem is to identify more
genes crucial to the somatotrope/lactotrope cell identities, which has been the
goal of this work. Only with a more complete understanding of the set of genes
that make a somatotrope a somatotrope can one deal with classifying cells in
which the hormones-- currently the only landmarks used to determine cell
identity-- are perturbed. Thus, while GH/PRL dual positive cells that arise from
the deletion of Nupr1 may appear identical to the somatolactotropes that are
observed at low frequencies in wild type mouse pituitaries insofar as they both
co-express GH and PRL, they may in reality represent two different cell types.
Further study of the somatotrope, lactotrope, and somatolactotrope cell identities
will be needed to resolve this dilemma. The work presented here in
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characterizing the transcriptomes of the somatotropes and lactotropes provides a
critical resource that will be essential in reaching that goal.
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Figures and legends

Figure 13. Prl-Cre mouse line produces lactotrope-specific expression of
Cre recombinase. A. Schematic of Prl-Cre transgene. The Cre ORF was
inserted into the second exon of the Prl gene in the R23-441I3 BAC via BAC
recombineering. The transgene preserves approximately 50 kb of upstream and
downstream sequence flanking the Prl locus to include any previously
undescribed regulatory elements. B. Immunofluorescence microscopy of
dispersed pituitary cells from Prl-Cre/ZsGreen mice carrying transgenes for both
the Prl-Cre and a ZsGreen fluorescent reporter preceded by a lox-stop-lox
element such that ZsGreen is only expressed in cells that also express Cre
recombinase. Somatotropes are indicated by red arrows, while lactotropes are
indicated by white arrows. C. Quantification of somatotropes and lactotropes
expressing ZsGreen reporter detected in B.
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Figure 14. Deletion of Nr4a2 in mouse lactotropes causes a decrease in
prolactin positive cells. A. Representative immunofluorescence microscopy of
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dispersed mouse pituitary cells from control (left panel) and conditional Nr4a2
knockout (right panel) mice showing NR4A2+ lactotropes (red arrow) in control
mice and NR4A2- lactotropes (white arrow) in knockout mice. Staining for PRL is
shown in red, highlighting lactotrope cells while NR4A2 staining is shown in
green. B. Quantification of cells counted (N = 1500 cells) in blind study of the
number of GH, PRL, and GH/PRL positive cells in control and Nr4a2 conditional
knockout mice. C. Quantitative reverse transcription PCR of RNA isolated from
whole pituitaries of control and Nr4a2 knockout mice. mRNA levels for 5
landmark genes for the somatotrope and lactotrope lineages were assayed for
changes (N=2).
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Figure 15. Ablation of Nr4a2 causes and increase in POU1F1+/PRL- cells
and a corresponding decrease in POU1F1+/PRL+ cells. A. Representative
immunofluorescence microscopy images of dispersed pituitary cells from
Nr4a2flox/flox control mice. POU1F1, the primary known driver of both GH and PRL
expression, co-stains with PRL in lactotrope cells (white arrows). B.
Representative immunofluorescence microscopy images from Nr4a2flox/flox; Prl103

Cre mice. While POU1F1+/PRL+ are detected, their numbers relative to the
POU1F1+/PRL- cells (ratios) are significantly lower than in Nr4a2flox/flox littermate
control mice (* indicates significance of difference of ratios between the two
mouse genotypes). C. Quantification of immunofluorescence studies from B. N =
2 mice per experimental group.
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Figure 16. Conditional depletion of the lactotrope-enriched transcription
factor Pou4f1 fails to impact on Prl expression in adult mouse lactotrope
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cells. A. Representative immunofluorescence microscopy images of dispersed
pituitary cells from Pou4f1flox/flox control mice (left panel) and Pou4f1flox/flox; Prl-Cre
mice (right panel) exhibiting similar distributions of somatotrope and lactotrope
cells. Cells were stained with antibodies against prolactin (green) and growth
hormone (red), with DAPI staining (blue) marking nuclei. B. Representation of
somatotropes (GH+), lactotropes (PRL+), and GH/PRL dual positive
somatolactotropes in the pituitaries of Pou4f1flox/flox; Prl-Cre mice and control
littermates. These data are derived from the IF studies, as shown in A. C. RNA
expression of hallmark genes in total RNA of whole pituitaries from Pou4f1flox/flox;
Prl-Cre mice and control littermates. These data were generated by RT-PCR and
normalized to Gapdh expression. N=2. * indicates p-value <0.05.
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Figure 17. Conditional depletion of Nupr1 in somatotropes results in an
increase in Prl expression in the mouse pituitary with a corresponding
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increase in GH/PRL dual positive cells. A. qRT-PCR of total RNA isolated from
whole pituitary samples from Nupr1flox/flox; Gh-Cre and Nupr1flox/flox mice. N = 3
mice per genotype. B. Representative immunofluorescence microscopy images
of dispersed pituitary cells from Nupr1flox/flox mice, showing a typical distribution of
GH and PRL single positive cells (somatotropes and lactotropes). Images are
separated into nuclear DAPI staining (blue), growth hormone (green), prolactin
(red) as well as a merged image. Somatotropes are indicated by red arrows. C.
Representative immunofluorescence microscopy images of dispersed pituitary
cells from Nupr1flox/flox; Gh-Cre mice, showing multiple GH/PRL dual positive cells
(white arrows). D. Cell counts for GH positive somatotropes, PRL positive
lactotropes, and GH/PRL dual positive cells observed by immunofluorescence
microscopy presented as a percentage of total pituitary cells. N = 3 mice per
genotype, 300 cells counted per mouse.

108

Figure 18. Modified model for selective expression of Gh and Prl in
somatotropes and lactotropes (based in work in the current thesis). The
master regulatory transcription factor POU1F1 is present in both somatotropes
and lactotropes and occupies the promoters of the Gh and Prl genes. The
actions of POU1F1 at these sites is responsible for base-line expression of both
hormone genes in both lineages. The selective enrichment of Gh and Prl in their
respective somatotrope and lactotrope lineages reflects the reciprocal actions of
transcriptional enhancers and repressors. In somatotropes (left), the robust
expression of Gh, most likely stimulated via interactions of yet unidentified
factor(s) (“?”, dashed oval) with POU1F1, is complemented by a reciprocal
repression of Prl transcription by NUPR1. NUPR1 does not appear to act directly
on the Prl promoter; whether its repressive activity is linked to direct actions at a
site in cis to the Prl gene, or via indirect mechanism(s) is yet to be determined. In
lactotropes (right), Gh expression is postulated to be actively repressed (“?”,
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dashed oval), while Prl expression is selectively activated by the actions of
NR4A2. NR4A2 occupancy and activity is dependent on the actions of POU1F1.
NR4A2 acts in conjunction with an adjacently situated POU1F1 to enhance the
release of Pol II from the Prl promoter. This release activity allows the extension
of Pol II into the Prl gene body with consequent production of Prl mRNA.
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Supplemental Data

Supplemental Figure 7. Validation of Gh-Cre mouse line. A. Gh-Cre mice,
previously reported16, were obtained from the lab of Dr. Sally Camper. To
validate the mouse line, Gh-Cre mice were crossed with mice carrying a ZsGreen
transgene in which the expression of ZsGreen is controlled by a Lox-Stop-Lox
system such that cells which express Cre will also express ZsGreen. The
pituitaries of Gh-Cre/ZsGreen mice were disaggregated and stained with
antibodies against GH to mark somatotropes and against ZsGreen to mark Creexpressing cells. Of 200 somatotropes (GH+ cells) assayed, 182 (91%) were also
positive for ZsGreen, indicating robust Cre expression in somatotrope cells. B.
The same study was performed co-staining cells for both ZsGreen and PRL to
mark lactotrope cells. Of 200 lactotropes (PRL+ cells) assayed, 64 (32%) were
also positive for ZsGreen, consistent with previous reports16.
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Chapter V: Summary and Future Directions
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Summary
The anterior pituitary is composed of multiple cell types that are each
responsible for the production and regulated secretion of a given hormone. The
Pou1f1-dependent lineages-- the somatotropes, lactotropes, and thyrotropes-have been shown to be primarily regulated by Pou1f1 with few other factors
having been identified as part of this process. Here, we generated the first
transcriptome-wide view of gene expression in murine somatotropes and
lactotropes, giving an unprecedented view into their differential gene expression
as well as their many similarities. While our transcriptomic data revealed that the
somatotropes and lactotropes are overall quite similar cell types—an observation
that differs from the conventional model of these cells as well-distinguished,
discrete cell types—there also exist small, but crucial subsets of somatotrope
and lactotrope enriched genes that contribute to the distinct cell identities of
these populations.
Among the sets of differentially expressed genes that we identified in
somatotrope and lactotrope cells, we selected six transcription factors for further
study, and narrowed down this list of transcription factors. Using a cell line model
system, we found that the somatotrope enriched transcription factor, Nupr1, and
two lactotrope enriched factors, Nr4a2 and Pou4f1, had significant functional
impacts on the expression of genes that are known to be crucial to the
somatotrope and lactotrope cell identities. While Nr4a2 and Pou4f1 were
observed to have a positive regulatory effect on the expression of Prl, Nupr1
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exerted a repressive effect on the expression of both Prl and another crucial
lactotrope gene, Drd2, in our cell line model system. These observations
suggested the existence of transcription factors that are expressed in either the
somatotrope or lactotrope cells that can influence the expression of genes central
to cell identity through a variety of mechanisms, both enhancing and repressive.
We next sought to test the functions of these transcription factors in
mouse models. After generating or acquiring the required mouse lines carrying
floxed alleles of each transcription factor as well as transgenes that express Cre
recombinase in either a somatotrope or a lactotrope specific manner, we
assayed the impact of ablating these transcription factors in primary mouse
pituitary. Assays of the ablation of Pou4f1 failed to reveal a functional impact on
Prl expression as predicted by our cell line model studies, and thus it was
excluded from further study. Ablation of the somatotrope enriched factor, Nupr1,
led to ectopic expression of PRL in cells that co-express GH, consistent with the
prediction that Nupr1 is a repressor of Prl in somatotrope cells. Lastly, ablation of
the lactotrope transcription factor Nr4a2 caused a loss of approximately half of all
PRL+ cells in the pituitaries of knock-out mice. This loss was further
characterized and found to be the result of lactotrope cells ceasing expression of
Prl rather than a failure of lactotrope cells to develop in earlier stages of pituitary
development. We focused on Nr4a2 to elucidate the mechanism by which it
enhances Prl expression. These studies revealed that NR4A2 directly binds to
the Prl promoter and enhances the release of RNA polymerase II from the Prl
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promoter. Our in vivo mouse studies, focusing on the subset of three transcription
factors that were identified by our transcriptomic analyses and validated in the
cell culture studies, reveal a diversity of actions carried out by transcription
factors in the somatotrope and lactotrope cells that are essential to maintaining
cell identity.
Taken together, the data presented in this dissertation reconfigure and
expand upon the previous standard model of pituitary cell identity. Pou1f1 acts in
conjunction with other transcription factors that are enriched in either cell type.
These transcription factors can exert either enhancing or repressive effects on
the expression of the Prl gene, and the set of transcription factors highlighted in
this dissertation is likely to represent only a subset of the factors involved in this
process. These data suggest that the somatotrope and lactotrope cells are cells
with highly similar transcriptomes, but the expression of a small set of
somatotrope and lactotrope genes is sufficient to maintain separate cell
identities.
Future directions
Determination of the mechanism of action of Nr4a2
Although progress has been made in determining the mechanism by
which Nr4a2 increases Prl expression, some questions remain open. An
outstanding question regarding Nr4a2 is what co-factor(s) are recruited to the Prl
promoter in order to enhance the release of Pol II. To resolve this question,
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future studies will utilize co-immunoprecipitation of NR4A2 in transfected Pit1/Triple cells (which express endogenous Pou1f1) coupled with mass
spectrometry. A reciprocal co-immunoprecipitation of POU1F1 will allow analysis
of the complex at the Prl promoter in the absence of NR4A2 (untransfected Pit1/Triple cells). By precipitating NR4A2 along with nearby and/or complexed
proteins, we will be able to identify additional factors that are recruited in the
presence of NR4A2, and the use of mass spectrometry will provide an unbiased
view of these factors. Identified factors will then be the subject of mechanistic
studies to determine their role in enhancing Prl expression.
Another question is whether Nr4a2 impacts other genes beyond Prl. While
Prl was the only gene affected by the presence of Nr4a2 in our cell based
studies, these studies assayed a small selection of known somatotrope and
lactotrope genes in order to establish an initial screening of Nr4a2 functions. It is
possible that other genes are impacted by Nr4a2 beyond the genes assayed in
our studies, but their identification would require a broad approach. To identify
other genes that are impacted by Nr4a2, RNA-seq will be performed on
Nr4a2flox/flox; Prl-Cre and Nr4a2flox/flox mice. Differential gene expression analyses
will permit the identification of genes that are impacted by the loss of Nr4a2
specifically in lactotrope cells, generating a data set that will highlight genes for
further study and synergize with the above Co-IP experiments to provide a better
understanding of the role of Nr4a2 in lactotropes and the full impact of the loss of
Nr4a2 on the lactotrope population.
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Determination of the mechanism of action of Nupr1 in somatotropes
Unlike Nr4a2, the potential mechanism of action of the somatotropeenriched factor Nupr1 is not currently understood. ChIP of NUPR1 has
unfortunately not been feasible due to a lack of ChIP grade antibodies and
known NUPR1 binding sites to serve as positive controls, and thus it is not
known at present if NUPR1 binds the Prl promoter. Future studies will take a
genome-wide approach to identifying targets of Nupr1 regulation by performing
RNA-seq experiments comparing gene expression in somatotrope-specific Nupr1
knockout mice to floxed control mice in order to identify genes impacted by
Nupr1 expression in somatotropes. Genes that are identified as being
differentially expressed in the absence of Nupr1 will be assayed for a role in
repression of Prl using cell line models.
Although ChIP of NUPR1 is not currently feasible without knocking an
epitope tag into the endogenous mouse Nupr1 locus, changes in chromatin
modifications at the Prl promoter can be assayed in the presence and absence of
Nupr1. Pit-1/Triple cells expressing Nupr1 exhibit a repression of both Prl and
Drd2 expression, which may be the result of repressive chromatin marks such as
H3K27me and/or H3K9me at the promoters of these genes. This possibility will
be assayed by comparing the H3K27me profiles at the promoters of Prl and Drd2
in Pit-1/Triple cells in the presence and absence of Nupr1 expression. An
increase in repressive chromatin marks when Nupr1 is expressed would indicate
that Nupr1 operates by in some manner recruiting these histone marks to the
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promoters of the genes it represses, giving an insight into the mechanism by
which Nupr1 represses Prl expression in mouse somatotropes.
Characterization of impact(s) of identified transcription factors in earlier
stages of pituitary cell development
As previously discussed, conditional deletion of Pou4f1 using a Prl-Cre
mouse line did not yield any impact on Prl expression in mice (Chapter IV)
despite an observed impact on Prl expression in Pit-1/Triple cells (Chapter III).
One possible explanation for this discrepancy is that Pou4f1 acts on the
lactotrope lineage at a developmental stage prior to Prl expression, and thus the
Prl-Cre is expressed too late to trigger an effect in Pou4f1flox/flox; Prl-Cre mice.
This problem could be further investigated in future studies through the use of a
Cre recombinase under the regulatory control of a gene expressed prior to Prl,
such as Pou1f1. As the required mice carrying floxed alleles for Pou4f1, Nupr1,
and Nr4a2 are all established in the lab, this study can be expanded to all three
transcription factors of interest. Conditional deletion of Pou4f1 in mice carrying a
Pou1f1-Cre recombinase will be assayed for a reduction in either the number of
lactotropes, or the level of Prl expression in the lactotropes. Conditional deletions
of the remaining transcription factors, Nr4a2 and Nupr1 in Pou1f1-Cre mice will
be assayed for any changes in their established impacts on lactotrope and
somatotrope cells, respectively, when deleted at an earlier stage in pituitary
development. These studies will provide a better understanding of how the
transcription factors identified in this thesis function in the anterior pituitary.
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Materials and Methods
Cell and transgenic mouse lines. Mice carrying the previously described
Gh-GFP and Prl-DsRed transgenes were mated to generate compound
transgenic mice carrying both reporter constructs (GFP+/DsRed+)45,46. Mice
carrying the previously described Gh-Cre16 or the newly generated Prl-Cre alleles
were crossed with either the existing Nr4a2flox 97, existing Pou4f1flox 96, or the
newly generated Nupr1flox alleles to generate the appropriate conditional
knockout mice for the described studies. All mice were of a hybrid CD1 x
B6SJLF1/J background, and were aged to 6-8 weeks before use in experiments
to allow for the complete maturation of the pituitary gland. All mice used in these
studies were virgin females. All mouse studies were reviewed and approved by
the University of Pennsylvania Laboratory Animal Use and Care Committee. The
Pit-1/Triple and Pit-1/0 cell lines, previously described28, were cultured in
Dulbecco's modified eagle medium (DMEM) (Life Technologies) plus 10% fetal
bovine serum (FBS) along with 1× antibiotic-antimycotic solution (Invitrogen).
Cells were removed from plates for the purposes of passaging and for harvesting
using a 0.05% Trypsin-EDTA solution (Life Technologies).
Generation of transgenic mouse lines. The existing GH-GFP mouse
line45, provided to our lab as a cosmid containing the GH-GFP transgene, was
modified with sub-cloning techniques. Briefly, an MluI digestion of the GH-GFP
cosmid released a fragment containing the GFP ORF as well as upstream and
downstream Gh sequence. This fragment was sub-cloned into a vector (pGEM-4)
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and inverse PCR was performed using primers that flanked the sequence
corresponding to the first 24 amino acids of GH such that only the first 8 amino
acids would be preserved in the PCR product. This PCR product was then
ligated to form a plasmid containing a truncated version of the GH-GFP
sequence that contains only 8 amino acids of GH prior to the beginning of the
GFP sequence. Such a truncation has been previously demonstrated to ablate
the secretion of the linked protein45. Lastly, the plasmid was again digested with
MluI to release the modified Gh-GFP and ligated back into the full length cosmid
from which it was extracted. This cosmid was then linearized and microinjected
into mouse embryos by the Penn Transgenic Mouse Facility and Gh-GFP lines
were established.
The Prl-Cre transgenic mouse line was generated via a previously
described BAC recombineering method94. Briefly, a shuttle vector containing the
Cre ORF flanked by 500 bp of sequence homologous to the desired insertion site
(the beginning of exon 2 of the Prl ORF) in the mouse Prl locus was generated
with conventional sub-cloning techniques. Then, bacterial cells were cotransformed with the shuttle vector as well as the RP23-441I3 BAC, obtained
from the BACPAC repository. This BAC contains the mouse Prl locus as well as
over 50 kb of upstream and downstream sequence. Co-transformed cells were
grown in selective media and screened for co-integrates. After obtaining shuttle
vector/BAC co-integrates, a second round of selection was performed to select
for resolution of the co-integrate. Resolved BACs containing the Cre ORF in the
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proper site within the BAC were confirmed by PCR and pulse field gel analysis.
Prl-Cre BAC DNA was linearized by restriction enzyme digestion, purified by gel
extraction, and provided to the Penn Transgenic Mouse facility for microinjection
into mouse embryos. Prl-Cre mouse lines were confirmed by genotyping after
birth and proper function of the Prl-Cre transgene was validated by crossing the
Prl-Cre mouse line with a previously described reporter line. The Nupr1flox mouse
line was generated by the Penn CRISPR/Cas9 Mouse Targeting facility using
conventional CRISPR/Cas9 methodologies to target LoxP sites flanking the
second exon of the Nupr1 locus, as deletion of this exon has been previously
reported to successfully ablate NUPR1 activity98.
Fluorescence activated cell sorting. Pituitaries from female
GFP+/DsRed+ mice were harvested at 6-8 weeks and dissociated mechanically in
enzyme free cell dissociation buffer (Life Technologies) before being passed
through a 40 μm filter into DMEM + 10% FBS culture media and centrifuged at
1000 g for 5 minutes. After centrifugation, cells were resuspended in PBS + 0.1%
BSA and layered onto a PBS + 4% BSA cushion and centrifuged a second time
at 100 g for 5 minutes to remove cell debris. Cell pellets were resuspended in
PBS + 0.1% BSA, 1 μg of DAPI was added directly to the samples, and the cells
were sorted on a FACS Aria II platform (BD Biosciences) directly into Trizol LS
reagent (Thermo Fisher Scientific). The cell sorting was performed by the Flow
Cytometry & Cell Sorting Facility at University of Pennsylvania.
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RNA isolation and RNA-sequencing. RNA from FACS sorted cells was
isolated (Trizol LS protocol; Thermo Fisher Scientific) using 10 µg of GlycoBlue
coprecipitant (Thermo Fisher Scientific) as a carrier. RNA quality and
concentration were assayed using the RNA 6000 Pico kit (Agilent) with a 2100
BioAnalyzer (Agilent) platform. High quality RNA samples, defined by RIN scores
of >7, were submitted to the University of Pennsylvania Next Generation
Sequencing Core (NGSC) for analysis. Each sample was amplified using the
Ovation ultralow RNA-seq library system (Nugen) and libraries were sequenced
on the HiSeq 2500 platform (Illumina). Sequencing data was mapped and
analyzed by the Penn Next-Generation Sequencing Core (NGSC). GEO
accession number for sequencing data: GSE118863.
Cell transfection assays. The cDNA of Nupr1 was amplified from mouse
pituitary cDNA, and cDNAs for the other studied transcription factors were
obtained from OriGene or Addgene and sub-cloned into an IRES GFP vector
(Addgene plasmid #51406). The expression of the cDNA and GFP in this vector
is controlled by the CMV promoter. Pit-1/Triple and Pit-1/0 cells were transfected
with 10 μg of plasmid using the TransIT-293 transfection reagent (Mirus Bio). In
co-transfection assays, cells were transfected with 5 µg of each plasmid to
maintain the DNA: TransIT-293 ratio as recommended by the manufacturer. Two
days after transfection, GFP+ cells were FACS sorted using the method and
platform described above. RNA was isolated from the GFP+ cells as described
above and cDNA was generated using the SuperScript III reverse transcription kit
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(Life Technologies). Quantitative real time PCR was performed using the Fast
SYBR Green Master Mix kit (Applied Biosystems) on a QuantStudio 7 Flex
(Applied Biosystems) platform. qRT-PCR assays were done in biological
triplicate, and all samples were normalized to the housekeeping gene Gapdh,
and compared to cells transfected with an empty vector by the ΔΔCt method 101.
All transfections were performed using approximately 1.6 million cells per
sample, grown to 80% confluence in 10 cm plates. Amplification primer
sequences: Gh: 5’-gcccaggctgctttctgc-3’ and 5’-caattccatgtcggttctctgc-3’. Prl: 5’aggggtcagcccagaaagc-3’ and 5’-tcaccagcggaacagattgg-3’. Pou1f1: 5’aggtgggagcaaacgaaagg-3’ and 5’-gctccccgaagtgtctctcc-3’. Ghrhr: 5’tcacttcggctcagcacagg-3’ and 5’-ggcaagccacagggtatgg-3’. Drd2: 5’tgaacctgtgtgccatcagc-3’ and 5’-gacagtaactcggcgcttgg-3’. Gapdh: 5’agcttaggttcatcaggtaaactcagg-3’ and 5’-cgttcacaccgaccttcacc-3’. Nr4a2: 5’gatcagtgccctcgtcagagc-3’ and 5’-gtcagggtttgcctggaacc-3’. Nupr1: 5’gcgggcatgagaggaagc-3’ and 5’-gctgggtgtggtgtctgtgg-3’. Rxrg: 5’aagtttcccaccggctttgg-3’ and 5’-gtggctgtccattggcttcc-3’. Pou4f1: 5’agtacccgtcgctgcactcc-3’ and 5’-gtccaggctggcgaagagg-3’.
Immunofluorescence microscopy. Pituitaries were disaggregated and
prepared using the same process as noted above for FACS. The
immunofluorescent staining was performed as previously described102. Briefly,
the disaggregated cells were placed on Poly-L-lysine coated slides and
incubated at room temperature for 10 minutes to allow the cells to adhere to the
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slide. After attaching to the slides, cells were fixed in 4% formaldehyde for 10
minutes, then washed three times with PBS for 5 minutes per wash. Cells were
permeabilized in a solution of 0.5% triton X-100 and 0.5% saponin for 10
minutes. The cells were washed with PBS before being incubated in a blocking
buffer of 4X SSC, 2% BSA, 0.1% Tween 20, and 15% donkey serum for 20
minutes at room temperature. After blocking, slides were incubated with
antibodies specific to proteins of interest for 1 hour at room temperature, washed
three times in PBS, then incubated for one hour at room temperature with
secondary antibodies conjugated to fluorophores for detection. After incubation
with secondary antibodies, the slides were washed a final time, incubated for 1
minute in 1mg/ml DAPI, and cover slips were attached. Slides were imaged with
a Leica SP8 confocal microscope platform. Images were analyzed using Fiji
software103. Antibodies used for each transcription factor are as follows: NUPR1
(Thermo-Fisher PA5-65826, RRID: AB_2662159104), RXRG (Santa Cruz SC514134, RRID: AB_2737293105), TBX19 (Santa Cruz SC-22656, RRID:
AB_2200381106), PPARG (Abcam 55296, RRID: AB_944767107), NR4A2 (Abcam
ab41917, RRID: AB_776887108) and POU4F1 (Abcam ab81213, RRID:
AB_1640222109).
Chromatin Immunoprecipitation (ChIP). ChIP assays were performed
as previously described110. Chromatin was isolated from approximately 200,000
FACS sorted transfected cells per sample and chromatin from 100,000 cells was
used per ChIP reaction. For the purposes of performing ChIP assays, Pit-1/0
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cells were transfected with 20 µg of plasmid DNA using Lipofectamine 3000
(Thermo Scientific) per the manufacturer’s directions to achieve higher
transfection efficiency. Antibodies specific for NR4A2 (Abcam ab41917, RRID:
AB_776887) and POU4F1 (Abcam ab81213, RRID: AB_1640222) were used in
the respective assays. H3K27ac ChIP was performed using antibody ab4279
(RRID: AB_2118291111) and H3K4me4 ChIP was performed using antibody
ab8580 (RRID:AB_306649). A rabbit antibody specific for POU1F1 was
generated by Alpha Diagnostics (RRID: AB_2732812112) using the antigen
sequence: PLLAEDPAASEFKQELRRKSKL. This affinity purified antibody was
demonstrated to be specific for POU1F1 by Western blot analysis
(Supplemental Figure 2). Normal rabbit IgG (Millipore) was used as a control in
all ChIP assays. Input and bound DNAs were amplified by qRT-PCR using the
same QuantStudio 7 Flex platform noted above. A serial dilution of the input
chromatin was used to determine the linear range of the amplification and the
enrichment of the bound DNA was calculated as a percentage of the input. ChIP
of primary mouse pituitary cells was performed using the same protocol, with
cells being collected by FACS as above prior to isolation of chromatin.
Amplification primer sequences: Gh promoter: 5’-gccttggggtcgaggaaaac-3’ and
5’-gggatttgcgcatgcttacc-3’. Prl upstream control: 5’-gaactggaagctgttgaacttgc-3’
and 5’-ggtcttgggaactgaacttgg-3’. Prl promoter: 5’-tggccaatgtcttcctgaatatg-3’ and
5’-cactggctttataaacctttgaca-3’. Prl downstream control: 5’catgcattctaccaaaagggtagg-3’ and 5’-tgcatctctatagcacttggtttatcc-3’. MyoD
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promoter: 5’-gcgtatggctgccagtctct-3’ and 5’-tgtagtagggcggagcttgg-3’. Pou4f1
enhancer: 5’-cgcgaaaccaacaaagagttttc-3’ and 5’-ctgtagcgcgtttaaataaatgaagtg-3’.

126

REFERENCES
1.

2.
3.
4.
5.

6.
7.

8.

9.

10.
11.
12.
13.
14.

15.

16.
17.

Burrows HL, Douglas KR, Seasholtz AF, Camper SA. Genealogy of the Anterior Pituitary
Gland: Tracing a Family Tree. Trends in endocrinology and metabolism: TEM.
1999;10(9):343-352.
Zhu X, Gleiberman AS, Rosenfeld MG. Molecular physiology of pituitary development:
signaling and transcriptional networks. Physiological reviews. 2007;87(3):933-963.
Park HL, Bai C, Platt KA, et al. Mouse Gli1 mutants are viable but have defects in SHH
signaling in combination with a Gli2 mutation. Development. 2000;127(8):1593-1605.
Treier M, O'Connell S, Gleiberman A, et al. Hedgehog signaling is required for pituitary
gland development. Development. 2001;128(3):377-386.
Musumeci G, Castorina S, Castrogiovanni P, et al. A journey through the pituitary gland:
Development, structure and function, with emphasis on embryo-foetal and later
development. Acta histochemica. 2015;117(4-5):355-366.
Ingraham HA, Chen RP, Mangalam HJ, et al. A tissue-specific transcription factor
containing a homeodomain specifies a pituitary phenotype. Cell. 1988;55(3):519-529.
He X, Treacy MN, Simmons DM, Ingraham HA, Swanson LW, Rosenfeld MG. Expression
of a large family of POU-domain regulatory genes in mammalian brain development.
Nature. 1989;340(6228):35-41.
Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE. A mutation in the
POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency.
Science. 1992;257(5073):1115-1118.
Cohen LE, Wondisford FE, Radovick S. Role of Pit-1 in the gene expression of growth
hormone, prolactin, and thyrotropin. Endocrinology and metabolism clinics of North
America. 1996;25(3):523-540.
Pfaffle RW, Blankenstein O, Wuller S, Kentrup H. Combined pituitary hormone
deficiency: role of Pit-1 and Prop-1. Acta Paediatr Suppl. 1999;88(433):33-41.
Camper SA, Saunders TL, Katz RW, Reeves RH. The Pit-1 transcription factor gene is a
candidate for the murine Snell dwarf mutation. Genomics. 1990;8(3):586-590.
Frawley LS. Mammosomatotropes: current status and possible functions. Trends in
endocrinology and metabolism: TEM. 1989;1(1):31-34.
Frawley LS, Boockfor FR. Mammosomatotropes: presence and functions in normal and
neoplastic pituitary tissue. Endocrine reviews. 1991;12(4):337-355.
Villalobos C, Nunez L, Garcia-Sancho J. Phenotypic characterization of multi-functional
somatotropes, mammotropes and gonadotropes of the mouse anterior pituitary.
Pflugers Archiv : European journal of physiology. 2004;449(3):257-264.
Luque RM, Amargo G, Ishii S, et al. Reporter expression, induced by a growth hormone
promoter-driven Cre recombinase (rGHp-Cre) transgene, questions the developmental
relationship between somatotropes and lactotropes in the adult mouse pituitary gland.
Endocrinology. 2007;148(5):1946-1953.
Nasonkin IO, Potok MA, Camper SA. Cre-mediated recombination in pituitary
somatotropes. Genesis. 2009;47(1):55-60.
Borrelli E, Heyman RA, Arias C, Sawchenko PE, Evans RM. Transgenic mice with inducible
dwarfism. Nature. 1989;339(6225):538-541.
127

18.

19.

20.

21.

22.

23.

24.
25.

26.

27.

28.

29.
30.
31.

32.
33.
34.

Castrique E, Fernandez-Fuente M, Le Tissier P, Herman A, Levy A. Use of a prolactinCre/ROSA-YFP transgenic mouse provides no evidence for lactotroph
transdifferentiation after weaning, or increase in lactotroph/somatotroph proportion in
lactation. The Journal of endocrinology. 2010;205(1):49-60.
Fu Q, Gremeaux L, Luque RM, et al. The adult pituitary shows stem/progenitor cell
activation in response to injury and is capable of regeneration. Endocrinology.
2012;153(7):3224-3235.
Fu Q, Vankelecom H. Regenerative capacity of the adult pituitary: multiple mechanisms
of lactotrope restoration after transgenic ablation. Stem cells and development.
2012;21(18):3245-3257.
Mangalam HJ, Albert VR, Ingraham HA, et al. A pituitary POU domain protein, Pit-1,
activates both growth hormone and prolactin promoters transcriptionally. Genes &
development. 1989;3(7):946-958.
Radl D, De Mei C, Chen E, Lee H, Borrelli E. Each individual isoform of the dopamine D2
receptor protects from lactotroph hyperplasia. Molecular endocrinology.
2013;27(6):953-965.
Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. Regulation of the
pituitary somatotroph cell by GHRH and its receptor. Recent progress in hormone
research. 2000;55:237-266; discussion 266-237.
Wang J, Scully K, Zhu X, et al. Opposing LSD1 complexes function in developmental gene
activation and repression programmes. Nature. 2007;446(7138):882-887.
Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator
exchange complex required for transcriptional activation by nuclear receptors and other
regulated transcription factors. Cell. 2004;116(4):511-526.
Brinkmeier ML, Davis SW, Carninci P, et al. Discovery of transcriptional regulators and
signaling pathways in the developing pituitary gland by bioinformatic and genomic
approaches. Genomics. 2009;93(5):449-460.
Calderon MJ, Ploegman AG, Bailey B, Jung DO, Navratil AM, Ellsworth BS. Loss of Foxm1
Results in Reduced Somatotrope Cell Number during Mouse Embryogenesis. PloS one.
2015;10(6):e0128942.
Sizova D, Ho Y, Cooke NE, Liebhaber SA. Research resource: T-antigen transformation of
pituitary cells captures three novel cell lines in the Pit-1 lineage. Molecular
endocrinology. 2010;24(11):2232-2240.
Jabaudon D. Fate and freedom in developing neocortical circuits. Nature
communications. 2017;8:16042.
Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell.
2008;132(4):631-644.
Zhao X, Wu J, Zheng M, Gao F, Ju G. Specification and maintenance of oligodendrocyte
precursor cells from neural progenitor cells: involvement of microRNA-7a. Molecular
biology of the cell. 2012;23(15):2867-2878.
Hoyler T, Klose CS, Souabni A, et al. The transcription factor GATA-3 controls cell fate
and maintenance of type 2 innate lymphoid cells. Immunity. 2012;37(4):634-648.
Zhu X, Wang J, Ju BG, Rosenfeld MG. Signaling and epigenetic regulation of pituitary
development. Current opinion in cell biology. 2007;19(6):605-611.
Andersen B, Rosenfeld MG. Pit-1 determines cell types during development of the
anterior pituitary gland. A model for transcriptional regulation of cell phenotypes in
128

35.
36.
37.

38.
39.

40.

41.
42.

43.

44.

45.

46.

47.

48.

49.

50.

mammalian organogenesis. The Journal of biological chemistry. 1994;269(47):2933529338.
Vankelecom H, Chen J. Pituitary stem cells: where do we stand? Molecular and cellular
endocrinology. 2014;385(1-2):2-17.
Rizzoti K. Adult pituitary progenitors/stem cells: from in vitro characterization to in vivo
function. The European journal of neuroscience. 2010;32(12):2053-2062.
Nunez L, Villalobos C, Senovilla L, Garcia-Sancho J. Multifunctional cells of mouse
anterior pituitary reveal a striking sexual dimorphism. The Journal of physiology.
2003;549(Pt 3):835-843.
Tatsumi K, Miyai K, Notomi T, et al. Cretinism with combined hormone deficiency
caused by a mutation in the PIT1 gene. Nature genetics. 1992;1(1):56-58.
Nelson C, Albert VR, Elsholtz HP, Lu LI, Rosenfeld MG. Activation of cell-specific
expression of rat growth hormone and prolactin genes by a common transcription
factor. Science. 1988;239(4846):1400-1405.
Nakane PK. Classifications of anterior pituitary cell types with immunoenzyme
histochemistry. The journal of histochemistry and cytochemistry : official journal of the
Histochemistry Society. 1970;18(1):9-20.
Ramirez MC, Ornstein AM, Luque GM, et al. Pituitary and brain dopamine D2 receptors
regulate liver gene sexual dimorphism. Endocrinology. 2015;156(3):1040-1051.
Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, et al. Pit-1 gene expression in human
lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene
expression. The Journal of clinical endocrinology and metabolism. 1996;81(9):33903396.
Davis SW, Castinetti F, Carvalho LR, et al. Molecular mechanisms of pituitary
organogenesis: In search of novel regulatory genes. Molecular and cellular
endocrinology. 2010;323(1):4-19.
Jones BK, Monks BR, Liebhaber SA, Cooke NE. The human growth hormone gene is
regulated by a multicomponent locus control region. Molecular and cellular biology.
1995;15(12):7010-7021.
Magoulas C, McGuinness L, Balthasar N, et al. A secreted fluorescent reporter targeted
to pituitary growth hormone cells in transgenic mice. Endocrinology.
2000;141(12):4681-4689.
He Z, Fernandez-Fuente M, Strom M, Cheung L, Robinson IC, Le Tissier P. Continuous online monitoring of secretion from rodent pituitary endocrine cells using fluorescent
protein surrogate markers. Journal of neuroendocrinology. 2011;23(3):197-207.
Gonzalez-Parra S, Argente J, Garcia-Segura LM, Chowen JA. Cellular composition of the
adult rat anterior pituitary is influenced by the neonatal sex steroid environment.
Neuroendocrinology. 1998;68(3):152-162.
Sasaki F, Iwama Y. Sex difference in prolactin and growth hormone cells in mouse
adenohypophysis: stereological, morphometric, and immunohistochemical studies by
light and electron microscopy. Endocrinology. 1988;123(2):905-912.
Aspe-Sanchez M, Moreno M, Rivera MI, Rossi A, Ewer J. Oxytocin and Vasopressin
Receptor Gene Polymorphisms: Role in Social and Psychiatric Traits. Frontiers in
neuroscience. 2015;9:510.
Murabe H, Shimatsu A, Ihara C, et al. Expression of somatostatin receptor (SSTR)
subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse
129

51.

52.
53.
54.

55.

56.

57.

58.

59.

60.

61.

62.

63.

64.

transcription-polymerase chain reaction. Journal of neuroendocrinology. 1996;8(8):605610.
Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin
receptor-specific analogs: effects on cell proliferation and growth hormone secretion in
human somatotroph tumors. The Journal of clinical endocrinology and metabolism.
2001;86(7):2976-2981.
Vankelecom H. Pituitary Stem Cells: Quest for Hidden Functions. In: Pfaff D, Christen Y,
eds. Stem Cells in Neuroendocrinology. Cham (CH)2016.
Konzak KE, Moore DD. Functional isoforms of Pit-1 generated by alternative messenger
RNA splicing. Molecular endocrinology. 1992;6(2):241-247.
Million Passe CM, White CR, King MW, Quirk PL, Iovanna JL, Quirk CC. Loss of the
protein NUPR1 (p8) leads to delayed LHB expression, delayed ovarian maturation, and
testicular development of a sertoli-cell-only syndrome-like phenotype in mice. Biology
of reproduction. 2008;79(4):598-607.
Maliza R, Fujiwara K, Tsukada T, Azuma M, Kikuchi M, Yashiro T. Effects of retinoic acid
on growth hormone-releasing hormone receptor, growth hormone secretagogue
receptor gene expression and growth hormone secretion in rat anterior pituitary cells.
Endocrine journal. 2016;63(6):555-561.
Guibourdenche J, Djakoure C, Porquet D, et al. Retinoic acid stimulates growth hormone
synthesis in human somatotropic adenoma cells: characterization of its nuclear
receptors. Journal of cellular biochemistry. 1997;65(1):25-31.
Koenig RJ, Brent GA, Warne RL, Larsen PR, Moore DD. Thyroid hormone receptor binds
to a site in the rat growth hormone promoter required for induction by thyroid
hormone. Proceedings of the National Academy of Sciences of the United States of
America. 1987;84(16):5670-5674.
Wu Y, Xu B, Koenig RJ. Thyroid hormone response element sequence and the
recruitment of retinoid X receptors for thyroid hormone responsiveness. The Journal of
biological chemistry. 2001;276(6):3929-3936.
Winczyk K, Pawlikowski M. Immunohistochemical detection of PPARgamma receptors in
the human pituitary adenomas: correlation with PCNA. Folia histochemica et
cytobiologica. 2005;43(3):137-141.
McCoy JM, Walkenhorst DE, McCauley KS, Elaasar H, Everett JR, Mix KS. Orphan nuclear
receptor NR4A2 induces transcription of the immunomodulatory peptide hormone
prolactin. Journal of inflammation. 2015;12:13.
Leblond-Francillard M, Picon A, Bertagna X, de Keyzer Y. High expression of the POU
factor Brn3a in aggressive neuroendocrine tumors. The Journal of clinical endocrinology
and metabolism. 1997;82(1):89-94.
Ingraham HA, Albert VR, Chen RP, et al. A family of POU-domain and Pit-1 tissue-specific
transcription factors in pituitary and neuroendocrine development. Annual review of
physiology. 1990;52:773-791.
Liu J, Lin C, Gleiberman A, et al. Tbx19, a tissue-selective regulator of POMC gene
expression. Proceedings of the National Academy of Sciences of the United States of
America. 2001;98(15):8674-8679.
Akcan N, Serakinci N, Turkgenc B, Bundak R, Bahceciler N, Temel SG. A Novel TBX19
Gene Mutation in a Case of Congenital Isolated Adrenocorticotropic Hormone
130

65.

66.

67.

68.

69.
70.
71.

72.

73.

74.
75.

76.

77.
78.
79.

80.

Deficiency Presenting with Recurrent Respiratory Tract Infections. Front Endocrinol
(Lausanne). 2017;8:64.
Lamolet B, Pulichino AM, Lamonerie T, et al. A pituitary cell-restricted T box factor, Tpit,
activates POMC transcription in cooperation with Pitx homeoproteins. Cell.
2001;104(6):849-859.
Booth A, Trudeau T, Gomez C, Lucia MS, Gutierrez-Hartmann A. Persistent ERK/MAPK
activation promotes lactotrope differentiation and diminishes tumorigenic phenotype.
Molecular endocrinology. 2014;28(12):1999-2011.
Syro LV, Sundsbak JL, Scheithauer BW, et al. Somatotroph pituitary adenoma with
acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism
and PKD1 mutation. Pituitary. 2012;15(3):342-349.
Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for
prolactin-secreting macroadenomas: results of a prospective multicenter study. The
Journal of clinical endocrinology and metabolism. 1985;60(4):698-705.
Whitelaw BC, Dworakowska D, Thomas NW, et al. Temozolomide in the management of
dopamine agonist-resistant prolactinomas. Clinical endocrinology. 2012;76(6):877-886.
Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. Journal of neurosurgery.
2011;114(5):1369-1379.
Haugen BR, Gordon DF, Nelson AR, Wood WM, Ridgway EC. The combination of Pit-1
and Pit-1T have a synergistic stimulatory effect on the thyrotropin beta-subunit
promoter but not the growth hormone or prolactin promoters. Molecular
endocrinology. 1994;8(11):1574-1582.
Diamond SE, Gutierrez-Hartmann A. The Pit-1beta domain dictates active repression and
alteration of histone acetylation of the proximal prolactin promoter. The Journal of
biological chemistry. 2000;275(40):30977-30986.
Cohen LE, Zanger K, Brue T, Wondisford FE, Radovick S. Defective retinoic acid
regulation of the Pit-1 gene enhancer: a novel mechanism of combined pituitary
hormone deficiency. Molecular endocrinology. 1999;13(3):476-484.
Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res.
2002;43(11):1773-1808.
Khan A, Fornes O, Stigliani A, et al. JASPAR 2018: update of the open-access database of
transcription factor binding profiles and its web framework. Nucleic acids research.
2018;46(D1):D1284.
Trieu M, Ma A, Eng SR, Fedtsova N, Turner EE. Direct autoregulation and gene dosage
compensation by POU-domain transcription factor Brn3a. Development.
2003;130(1):111-121.
Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes &
development. 1998;12(5):599-606.
Grunstein M. Histone acetylation in chromatin structure and transcription. Nature.
1997;389(6649):349-352.
Creyghton MP, Cheng AW, Welstead GG, et al. Histone H3K27ac separates active from
poised enhancers and predicts developmental state. Proceedings of the National
Academy of Sciences of the United States of America. 2010;107(50):21931-21936.
Pradeepa MM. Causal role of histone acetylations in enhancer function. Transcription.
2017;8(1):40-47.
131

81.

82.
83.
84.

85.

86.
87.
88.
89.
90.
91.
92.
93.

94.

95.

96.

97.

Matsumura Y, Nakaki R, Inagaki T, et al. H3K4/H3K9me3 Bivalent Chromatin Domains
Targeted by Lineage-Specific DNA Methylation Pauses Adipocyte Differentiation.
Molecular cell. 2015;60(4):584-596.
Jonkers I, Lis JT. Getting up to speed with transcription elongation by RNA polymerase II.
Nature reviews Molecular cell biology. 2015;16(3):167-177.
Chen FX, Smith ER, Shilatifard A. Born to run: control of transcription elongation by RNA
polymerase II. Nature reviews Molecular cell biology. 2018;19(7):464-478.
Zhao Y, Bruemmer D. NR4A orphan nuclear receptors: transcriptional regulators of gene
expression in metabolism and vascular biology. Arterioscler Thromb Vasc Biol.
2010;30(8):1535-1541.
Mahajan S, Saini A, Chandra V, et al. Nuclear Receptor Nr4a2 Promotes Alternative
Polarization of Macrophages and Confers Protection in Sepsis. The Journal of biological
chemistry. 2015;290(30):18304-18314.
Han YF, Cao GW. Role of nuclear receptor NR4A2 in gastrointestinal inflammation and
cancers. World journal of gastroenterology : WJG. 2012;18(47):6865-6873.
Erickson B, Sheridan RM, Cortazar M, Bentley DL. Dynamic turnover of paused Pol II
complexes at human promoters. Genes & development. 2018;32(17-18):1215-1225.
Phatnani HP, Greenleaf AL. Phosphorylation and functions of the RNA polymerase II
CTD. Genes & development. 2006;20(21):2922-2936.
Xu Z, Wei W, Gagneur J, et al. Bidirectional promoters generate pervasive transcription
in yeast. Nature. 2009;457(7232):1033-1037.
Young RS, Kumar Y, Bickmore WA, Taylor MS. Bidirectional transcription initiation marks
accessible chromatin and is not specific to enhancers. Genome biology. 2017;18(1):242.
Wei W, Pelechano V, Jarvelin AI, Steinmetz LM. Functional consequences of bidirectional
promoters. Trends in genetics : TIG. 2011;27(7):267-276.
Peel MT, Ho Y, Liebhaber SA. Transcriptome analyses of female somatotropes and
lactotropes reveal novel regulators of cell identity in the pituitary. Endocrinology. 2018.
Crenshaw EB, 3rd, Kalla K, Simmons DM, Swanson LW, Rosenfeld MG. Cell-specific
expression of the prolactin gene in transgenic mice is controlled by synergistic
interactions between promoter and enhancer elements. Genes & development.
1989;3(7):959-972.
Gong S, Yang XW, Li C, Heintz N. Highly efficient modification of bacterial artificial
chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of
replication. Genome research. 2002;12(12):1992-1998.
Madisen L, Zwingman TA, Sunkin SM, et al. A robust and high-throughput Cre reporting
and characterization system for the whole mouse brain. Nat Neurosci. 2010;13(1):133140.
Badea TC, Cahill H, Ecker J, Hattar S, Nathans J. Distinct roles of transcription factors
brn3a and brn3b in controlling the development, morphology, and function of retinal
ganglion cells. Neuron. 2009;61(6):852-864.
Kadkhodaei B, Alvarsson A, Schintu N, et al. Transcription factor Nurr1 maintains fiber
integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons.
Proceedings of the National Academy of Sciences of the United States of America.
2013;110(6):2360-2365.

132

98.

99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.

111.
112.

Vasseur S, Hoffmeister A, Garcia-Montero A, et al. p8-deficient fibroblasts grow more
rapidly and are more resistant to adriamycin-induced apoptosis. Oncogene.
2002;21(11):1685-1694.
Cushman LJ, Burrows HL, Seasholtz AF, Lewandoski M, Muzyczka N, Camper SA. Cremediated recombination in the pituitary gland. Genesis. 2000;28(3-4):167-174.
Winters SJ, Ghooray DT, Yang RQ, et al. Dopamine-2 receptor activation suppresses
PACAP expression in gonadotrophs. Endocrinology. 2014;155(7):2647-2657.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method.
Nat Protoc. 2008;3(6):1101-1108.
Ho Y, Liebhaber SA, Cooke NE. The role of the hGH locus control region in somatotrope
restriction of hGH-N gene expression. Molecular endocrinology. 2011;25(5):877-884.
Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for
biological-image analysis. Nature methods. 2012;9(7):676-682.
RRID: AB_2662159. In.
RRID: AB_2737293. In.
RRID: AB_2200381. In.
RRID: AB_944767. In.
RRID: AB_776887. In.
RRID: AB_1640222. In.
Shewchuk BM, Ho Y, Liebhaber SA, Cooke NE. A single base difference between Pit-1
binding sites at the hGH promoter and locus control region specifies distinct Pit-1
conformations and functions. Molecular and cellular biology. 2006;26(17):6535-6546.
RRID: AB_2118291. In.
RRID: AB_2732812. In.

133

